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Abstract 
Ketamine is a phencyclidine derivative N-Methyl D-Aspartate (NMDA) 
receptor antagonist used as an anaesthetic and analgesic. A florid non-
bacterial cystitis condition known as ketamine-induced cystitis (KIC) has 
recently been reported in abusers and prescription users of ketamine. 
Whilst the aetiological agent in patients withKIC is known, the mechanism 
of disease development is unknown. 
The aims of this study were to investigate the potential mechanisms of 
development of KIC and to establish potential links between KIC and other 
chronic non-bacterial cystitis conditions; interstitial cystitis (IC) and 
eosinophilic cystitis (EC). 
These aims were pursued under the following objectives; 
1. Investigate toxicity of ketamine and its primary metabolite nor-
ketamine on normal human urothelial (NHU) cell cultures. 
2. Describe human urothelial tissue damage caused by ketamine. 
3. Assess a possible relationship between ketamine exposure and 
development of KIC.  
The main findings were that;  
Ketamine and nor-ketamine were equally toxic to NHU cells in a 
concentration dependent manner.  
A specific NMDA receptor antagonist (MK-801) did not show any urothelial 
toxicity on its own but unexpectedly increased toxicity of ketamine when 
used in combination. 
Immunolabelling of the three individual KIC tissue sections demonstrated 
epithelial denudation and stromal inflammation with oedematous blood 
vessels. 
Results from a telephone questionnaire did not show any obvious 
relationship between prescription use of ketamine and development of 
KIC. 
Literature review suggested considerable similarities between the reported 
symptoms and clinical investigation findings of KIC to mainly EC and to 
some extent to IC. 
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In conclusion, the study indicated that ketamine might cause human 
urinary tract damage by impairing the barrier function of urothelium, 
inducing inflammation and resultant development of KIC. 
These experiments should form the basis for future research in to 
understanding the mechanisms of development of KIC and other difficult 
to treat chronic uropathies such as EC and IC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
Contents 
Abstract         2 
Contents         4 
Figures         8  
Tables         11 
Acknowledgments        12 
Author’s Declaration       13 
1 Introduction        14  
1.1 Ketamine-induced cystitis (KIC)    14 
1.1.1 History of Ketamine     14 
  1.1.2 Pharmacology of Ketamine    15 
  1.1.3 General signs/symptoms from ketamine use 15 
  1.1.4 Urological signs/symptoms from ketamine       
                     abuse/use      16 
  1.1.5 Aetiology of ketamine-induced cystitis (KIC) 17 
  1.1.6 Clinical investigation findings in KIC  18 
  1.1.7 Management of KIC     19 
 1.2 Non-bacterial cystitis      20 
  1.2.1 Interstitial Cystitis     20 
   1.2.1.1 Aetiology of IC    21 
   1.2.1.2 Signs/Symptoms of IC   22 
   1.2.1.3 Clinical Investigation Findings in IC 23 
   1.2.1.4 Management of IC    24 
  1.2.2 Eosinophilic Cystitis (EC)    25 
   1.2.2.1 Aetiology of EC    25 
   1.2.2.2 Signs/Symptoms of EC   26 
   1.2.2.3 Clinical investigation findings in EC 26 
   1.2.2.4 Management of EC   27 
 1.3 Discussion       27 
 1.4 Aims        29 
 1.5 Objectives       29 
 
 5 
2 Materials and Methods      30 
2.1 Cell Biology       31 
2.1.1 Passaging cells     31 
  2.1.2 Freezing cells      32 
  2.1.3 Bringing cells up from freezing   32 
  2.1.4 Cell counting using the improved Neubauer   
         haemocytometer     33 
  2.1.5 Preparing 96-well plates    33 
  2.1.6 Cell biomass assay     34 
2.2 Immunohistochemistry      34 
2.2.1 Formalin fixation of tissues for paraffin    
         wax embedding     34 
  2.2.2 Paraffin wax embedding of tissue specimens 35  
  2.2.3 Sectioning of paraffin wax-embedded tissue 35 
  2.2.4 Haematoxylin and Eosin staining of tissue   
         sections      36 
  2.2.5 Antigen retrieval methods for     
         immunoperoxidase experiments   36 
  2.2.6 Immunoperoxidase on Paraffin sections  37 
  2.2.7 Alcian Blue – Periodic Acid Schiff (AB-PAS)   
         with diastase digestion staining   39 
3 Establishing in vitro toxicity of ketamine    40 
3.1 Introduction       40 
 3.2 Aim        41 
3.3 Objectives       41 
 3.4 Experimental approach     42 
 3.5 Results        47 
 3.6 Discussion       56 
 3.7 Conclusions       57 
 
 
 
 6 
4 Characterisation of ketamine affected human    
urothelium        58 
4.1 Introduction       58 
 4.2 Aim        58 
  4.3 Objectives       58 
 4.4 Experimental approach     59 
4.5 Results        61 
4.5.1 Normal Urothelium     61 
  4.5.2 H&E staining of KIC tissue    61 
  4.5.3 Antibody panel for KIC tissues   62 
   4.5.3.1 Negative control sections for    
 antibody panel    67 
  4.5.4 Immunoperoxidase staining of KIC tissue   
         sections with antibodies from the panel  69 
4.5.4.1 Ki67      69 
   4.5.4.2 UPK3a     70 
   4.5.4.3 CK20.8     71 
   4.5.4.4 CK13      72 
   4.5.4.5 CK5      73 
   4.5.4.6 CK14      74 
   4.5.4.7 AB-PAS with diastase digestion   75 
   4.5.4.8 CD34      76 
   4.5.4.9 CD3      77 
   4.5.4.10 CD68     78 
   4.5.4.11 Mast Cell Tryptase   79 
   4.5.4.12 CD117     80 
   4.5.4.13 Anti-human NGFR   81 
 4.6 Discussion       82 
 4.7 Conclusions       84 
          
 
 
 7 
5 Relationship between dose, duration and frequency of  
ketamine use and development of ketamine-induced  
cystitis (KIC)        85 
 5.1 Introduction       85 
 5.2 Materials and Methods      86 
 5.3 Results        89 
 5.4 Discussion       93 
 5.5 Conclusions       94 
6 Discussion/Conclusions and future direction of research 95 
6.1 Possible mechanisms of development of     
      ketamine-induced cystitis     95  
  6.1.1 Cell Biology experiments    96 
  6.1.2 Immunohistochemistry experiments  97 
6.2 Is there a possible link between KIC and other chronic  
non-bacterial cystitis conditions i.e. interstitial cystitis (IC)  
and eosinophilic cystitis (EC)?     97 
6.2.1 Conclusions       99 
 6.3 Implications of the research     100 
 6.4 Future direction of research     101 
7 Appendix        102 
7.1 Suppliers        102 
7.2 Recipes        108  
7.2.1 Cell Biology      108 
   7.2.2 Histology      109 
7.3 Abbreviations        110 
8 References        112 
 
 
 
 
 
 8 
Figures 
Figure 3.1: Alamar blue reduction by different numbers of NHU  
       cells        43     
Figure 3.2: NHU cells treated with 0 - 10mM ketamine   47  
Figure 3.3: (data extracted from figure 3.2) NHU cells        
                  treated with 0 - 10mM ketamine    48 
Figure 3.4: NHU cells treated with 0 - 1.2mM ketamine  48 
Figure 3.5: NHU cells treated with 0.5 – 6mM ketamine  49 
Figure 3.6: NHU cells treated with 0.5 – 6mM nor-ketamine  49 
Figure 3.7: (data extracted from figures 3.5 and 3.6) Comparison     
        of toxicity induced in NHU cell cultures by ketamine or           
        nor-ketamine treatment     50  
Figure 3.8: Single ketamine treatment of NHU cells with      
                   0.6 – 1mM ketamine      51 
Figure 3.9: Daily ketamine treatment of NHU cells with  
                   0.6 – 1mM ketamine      51 
Figure 3.10: (data extracted from figures 3.8 and 3.9) Comparison  
         of control column (no ketamine treatment) of NHU  
         cells from both sets of plates    52 
Figure 3.11: (data extracted from figures 3.8 and 3.9) Comparison  
           of 0.6mM ketamine treatment of NHU cells from both 
           sets of plates       52 
 Figure 3.12: (data extracted from figures 3.8 and 3.9) Comparison  
           of 0.8mM ketamine treatment of NHU cells from both 
           sets of plates       53 
Figure 3.13: (data extracted from figures 3.8 and 3.9) Comparison  
           of 1mM ketamine treatment of NHU cells from both 
           sets of plates       53 
Figure 3.14: NHU cells treated with MK-801    54 
Figures 3.15 and 3.16: Comparison of number of NHU cells treated   
     with MK801, ketamine and a combination of  
 MK801 and ketamine     55 
 9 
 
Figure 4.1: H&E staining of a section of normal human ureter  61 
Figure 4.2: H&E staining of three individual KIC tissue sections 61 
Figure 4.3: Colonic metaplasia on H&E staining in one of the          
        individual KIC tissue section     62 
Figure 4.4: Ki67 positive human ureter section    62 
Figure 4.5: UPK3a positive human ureter section   63 
Figure 4.6: CK20.8 positive human ureter section   63 
Figure 4.7: CK13 positive human ureter section    63 
Figure 4.8: CK5 positive human ureter section    64 
Figure 4.9: CK14 positive human skin section    64 
Figure 4.10: AB-PAS with diastase digestion positive human  
         colon section       64 
Figure 4.11: CD3 positive human lymph node section   65  
Figure 4.12: CD34 positive human ureter section   65 
Figure 4.13: CD68 positive human lymph node section  65 
Figure 4.14: Mast cell tryptase positive human ureter section  66 
Figure 4.15: CD117 positive human ureter section   66 
Figure 4.16: Anti-human NGFR positive human ureter section 66 
Figures 4.17 and 4.18: Negative control sections of human ureter 67  
Figure 4.19: Negative control section of human skin   67 
Figure 4.20: Negative control section of human colon   68 
Figure 4.21: Immunoperoxidase labelling of KIC tissue sections  
                    with Ki67       69 
Figure 4.22: Immunoperoxidase labelling of KIC tissue sections  
                    with UPK3a       70 
Figure 4.23: Immunoperoxidase labelling of KIC tissue sections  
                    with CK20.8       71 
Figure 4.24: Immunoperoxidase labelling of KIC tissue sections  
                    with CK13       72 
Figure 4.25: Immunoperoxidase labelling of KIC tissue sections  
                    with CK5       73 
 10 
 
Figure 4.26: Immunoperoxidase labelling of KIC tissue sections  
                    with CK14       74 
Figure 4.27: AB-PAS with diastase digestion staining of KIC tissue  
         sections       75 
Figure 4.28: Immunoperoxidase labelling of KIC tissue sections  
                    with CD34       76 
Figure 4.29: Immunoperoxidase labelling of KIC tissue sections  
                    with CD3       77 
Figure 4.30: Immunoperoxidase labelling of KIC tissue sections  
                    with CD68       78 
Figure 4.31: Immunoperoxidase labelling of KIC tissue sections  
                    with Mast Cell Tryptase     79 
Figure 4.32: Immunoperoxidase labelling of KIC tissue sections  
                     with CD117       80 
Figure 4.33: Immunoperoxidase labelling of KIC tissue sections  
                     with Anti-human NGFR     81 
Figure 5.1: Telephone questionnaire used to investigate patients 
        using analgesic ketamine for any urinary tract  
        symptoms       87  
Figure 5.2: Management flow chart for any patients with urinary  
        symptoms using analgesic ketamine   88 
Figure 5.3: Patients excluded from the KIC questionnaire study and   
        reasons for their exclusion     89 
Figure 5.4: Frequency of different urinary tract symptoms in the  
 patients with possible urological damage from analgesic    
 ketamine use       91 
     
 
 
 
 
 11 
Tables 
Table 4.1: Initial antibody panel for the three inidividual KIC  
      tissue sections       60 
Table 5.1: Demographics, dose, duration and frequency of ketamine       
                 use in the patients found to have significant urinary tract  
      symptoms possibly from analgesic ketamine use  90  
Table 5.2: Demographics, dose, duration and frequency of ketamine  
                 use in the patients with no urinary tract symptoms after  
analgesic ketamine use     92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Acknowledgements 
I will like to acknowledge the following colleagues for their help and 
support with my research project: 
1) Professor Jennifer Southgate: for her supervision, support and 
guidance throughout my research. 
2) Mr Simon Fulford: for his supervision, support and guidance during 
my research as well as clinical training. I will further like to thank Mr 
Simon Fulford for his help with designing the KIC questionnaire, 
obtaining ethics approval and his support in carrying out the 
questionnaire. 
3) Dr Simon Baker: for his supervision, support and guidance 
throughout my research. 
4) Dr Adrian Mountford: for his co-supervision of my research project on 
the training committee. 
5) Dr Dawn Coverley: for her co-supervision of my research project on 
the training committee. 
6) Mrs Maya Harris: for securing funding for the study and, for helping 
me to set up the study and gain ethics approval. 
7) Dr Jens Stahlschmidt: for helping with interpreting the 
immunohistochemistry experiments. 
8) Dr Felix Wezel: for helping with performing one of the 
immunohistochemistry experiments. 
9) All current and past colleagues at the Jack Birch Unit of Molecular 
Carcinogenesis, Department of Biology, University of York with 
special thanks to Miss Jenny Hinley and Dr Catherine Thompson. 
10) I am also grateful to the Urology departments at the James Cook 
University Hospital, Middlesbrough and Southmead Hospital, Bristol 
for provision of ketamine-affected human urothelium biopsies for 
immunohistochemistry experiments.   
 
 
 13 
Author’s declaration 
The author would like to confirm that the work submitted is his own and 
that appropriate credit has been given to others where due. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
1 Introduction 
 
1.1 Ketamine-induced cystitis (KIC) 
1.1.1 History of Ketamine 
Ketamine is a phencyclidine derivative, first synthesised by Stevens in 
1962 at Parke-Davies laboratories (now part of Pfizer) and first used in 
humans by Corssen and Domino in 1965 [1]. In 1970, the United States 
Food and Drug Administration (FDA) approved ketamine for human use, 
and since then it has been used in the induction and maintenance of 
anaesthesia [2]. The first wide scale use of ketamine was on American 
soldiers in the Vietnam War. Recently, it is also increasingly used for the 
management of chronic pain ([3-5] and reviewed by [6]) and is under 
research to develop newer faster acting anti-depressants (reviewed by 
[7]). It is also used in the veterinary medicine and is commonly applied as 
a horse tranquilliser.  
Ketamine is fast becoming a popular recreational drug due to its easy 
availability and low prices. Anecdotal reports suggest that it is overtaking 
Ecstasy as the abused drug of choice on the dance and rave party scene. 
The main reason for this is that whereas Ecstasy leads to euphoria and 
other unwanted symptoms, ketamine abuse leads to a state of calm, 
cloudiness of memory and amnesia in association with an out of body 
experience known as the K-hole phenomenon. In this state, drug abusers 
have reported feelings of travelling through a light tunnel, near death 
experiences and speaking to God.  
On the streets, ketamine is known by the names of ‘Special K’, ‘Kit Kat’, 
‘Cat Valium’, ‘Vitamin K’ or just ‘K’. The routes of abuse include ingestion, 
inhalation and intravenous injections.  
Ketamine is an illegal drug in the UK and was labelled as a Class C drug 
on 1st January 2006. Due to the illegal nature of ketamine, the true number 
of drug abusers using it may never be known (reviewed by [8]). 
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1.1.2 Pharmacology of Ketamine 
Ketamine is used in clinical practice for its N-Methyl D-Aspartate (NMDA) 
receptor antagonist effect on neuronal cells which produces anaesthesia. 
It does not adversely affect the patient’s cardiovascular status during 
induction and is therefore the anaesthetic of choice in patients with 
haemodynamic instability.  
In addition to the NMDA receptor, it has promiscuous effects on multiple 
other binding sites including non-NMDA glutaminergic, monoaminergic, 
opioid, nicotinic and muscarinic cholinergic receptors (reviewed by [9]).  
Whereas the anaesthetic dose of ketamine is 0.5–2 mg/kg, recreational 
users report development of tolerance with continued use and admit to 
using up to 20 g/day (reviewed by [8]), and anecdotal reports of using up 
to 28g/day. This signifies the development of tolerance in recreational 
users abusing it in high doses. 
Ketamine is water soluble, has a pKa of 7.5 and a fat solubility 10 times 
that of thiopentone. It is metabolised by cytochrome p450 in the liver in to 
nor-ketamine (primary metabolite) and dehydronor-ketamine (secondary 
metabolite). Its redistribution half-life is 4.68 minutes. The excretory route 
is urine with an elimination half-life of 2.17 hours.  
 
1.1.3 General signs/symptoms from ketamine use 
Like all other anaesthetics, ketamine affects almost every system in the 
body. Its effects on different human physiological systems include: 
 Cardiovascular: tachycardia, hypertension 
 Respiratory: bronchodilation 
 Neurological: hallucinations, amnesia, mental clouding, loss of 
memory, impaired attention, out of body experiences (K-hole effect) 
 Gastrointestinal: nausea 
 Physical features: paralysed feeling, numbness  
 Muscles: dystonia 
Although some of these effects by ketamine are unwanted and bothering 
for patients in clinical practice, it still has wide applications in the induction 
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of anaesthesia, intensive care, sedation, paediatrics, bipolar disorders and 
to relieve bronchospasm in patients with asthma and chronic obstructive 
airway disease. 
 
1.1.4 Urological signs/symptoms from ketamine abuse/use 
Ketamine has been used for recreational purposes for many decades [10]. 
Although the World Health Organisation (WHO) Expert Committee 
meeting on Drug Dependence held in Geneva in 2003 raised concerns 
about the use of ketamine as a recreational drug and recommended a 
critical review [10], it was only around 2007 that reports of human 
urothelium damage from its abuse started appearing in literature [11]. 
Since then, more than 20 articles (case series, case reports, review and 
letters to the editors) have been published in the literature related to 
ketamine-induced cystitis (KIC) (reviewed by [12]).  
These reports from around the world have described development of non-
bacterial cystitis like symptoms not only in patients abusing high doses of 
ketamine [2, 13], but also in patients using it in much lower prescription 
doses for pain control [3, 14]. In a recently published study of recreational 
abusers of ketamine, 20.0% of frequent users (> 4 times per week), 6.7% 
of infrequent users (2 times per month, <4 per week) and 13.3% of ex-
users (abstinent from ketamine for a minimum of 84 days), spontaneously 
cited cystitis or bladder problems as being an experience or concern for 
them [15].  
At what time bladder symptoms typically start after ketamine abuse is 
unknown, but the time period may be from one month to several years 
[13]. Symptoms show a relationship dependent on dose and duration of 
abuse and this may signify that whereas the urinary tract recovers after 
initial injury, continuous abuse leads to permanent irreversible 
scarring/damage. 
The urinary signs and symptoms due to ketamine abuse/use reported in 
literature include: 
1. Dysuria [2, 13, 16-18] 
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2. Suprapubic pain [3, 18] 
3. Nocturia [18] 
4. Urinary frequency [2, 13, 16-18] 
5. Urinary urgency [2, 13, 16, 17] 
6. Urge incontinence [2, 16, 18] 
7. Haematuria [2, 13, 16-18] 
There are differing reports in the literature about the course of symptoms 
following abstinence from ketamine. Some authors have suggested that 
abstaining from ketamine improves the symptoms [3, 13, 14, 17], whereas 
others suggest that illicit ketamine use may lead to severe urinary tract 
problems that can be irreversible even after ketamine abuse has ceased 
[19]. There is another group of clinicians who have reported improvement 
in some, worsening in some and stable symptoms in others after 
abstinence [18, 20, 21]. 
 
1.1.5 Aetiology of ketamine-induced cystitis (KIC) 
Although the causative agent in patients with KIC is known, the 
aetiopathological mechanism of disease development remains unknown. 
A number of different theories have been proposed by Chu et al. [2] 
including: 
1. Direct effect of ketamine or its metabolites on bladder interstitial cells. 
2. Microvascular changes in the bladder and possibly kidney by 
ketamine and/or its metabolites. 
3. Indirect effect of ketamine by causing an autoimmune reaction 
against the bladder urothelium and submucosa due to circulating 
ketamine or urinary ketamine and its metabolites. 
4. Bacteriuria; Bacterial infection as the cause of KIC is unlikely as all 
patients in the study by Chu et al. had abacterial cystitis on 
presentation. The positive bacterial culture in the subsequent urine 
tests of two patients signified concomitant bacterial UTI instead of a 
genuine cause of the initial urinary symptoms. None of the patients in 
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the study showed any improvement in ketamine-related bladder 
symptoms after treatment with antibiotics.  
 
1.1.6 Clinical investigation findings in KIC 
Literature reports of different investigation findings in patients with KIC 
include: 
 Radiological investigations: 
1. Hydronephrosis; in one study of 11 patients, 5 had bilateral 
hydronephrosis, 4 had no hydronephrosis and in 2 patients the renal 
effects were unknown [13]. In another study of 59 patients, 26 had 
bilateral and 4 had unilateral hydronephrosis [2]. In a third study, 14% 
of patients with history of ketamine abuse presented with renal 
impairment and hydronephrosis [18]. The first 2 studies reported a 
higher incidence of upper urinary tract changes from ketamine abuse 
than reported in the third study. Of note is the fact that the first two 
studies  (Tsai et al. [13] and Chu et al. [2]) were published from the 
South East Asia (Taiwan and Hong Kong respectively), whereas the 
third study (Mason et al. [18]) is from the UK. This might signify either 
racial differences in ketamine effects on the urinary tract or different 
combinational effects due to different cultures (e.g. drug, alcohol, diet 
or environmental factors) or differences in the drug supply with 
different additives in different parts of the world. 
2. Small capacity bladder 
3. Papillary necrosis [2] 
 Urodynamics: 
Small capacity bladder [2, 13] 
 Cystoscopy: 
One or more of epithelial inflammation, neovascularisation, petechial 
(pinpoint) haemorrhages and erythematous bladder mucosa [2]. 
 Histology: 
1. Denuded epithelium [2, 16, 17] 
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2. Infiltration of tissues with granulocytes, predominantly eosinophils 
[13, 16, 18] 
3. Infiltration of tissues predominantly by lymphocytes and a variable 
number of eosinophils [2].  
4. Infiltration of tissues with mast cells [13] 
5. Infiltration of tissues with granulation tissue [2, 17] 
6. Urothelial atypia (nuclear enlargement and disorganisation) [16, 18] 
 Immunohistochemistry: 
1. High expression of p53 [16, 18] 
2. High expression of Ki67 [16, 18] 
3. Absence of CK20 expression [16, 18]. This means that although 
reactive atypia can be found in KIC samples, the negative CK20 rules 
out the possibility of carcinoma in situ [22]. 
 
1.1.7 Management of KIC 
Patients with KIC are difficult to manage. Uncooperative behaviour and 
missed clinical appointments is common among drug abusers and the 
same trend is followed by patients abusing ketamine. Unfortunately, there 
is no definite treatment therapy other than symptomatic treatment for 
patients who do seek medical attention. 
Abstaining from ketamine is the first step, which is not always easy. This is 
because although patients with KIC have troublesome urinary symptoms, 
they might continue abusing ketamine as the most effective way of 
suppressing their symptoms.  
There is no definite medical therapy in place but different clinicians have 
tried different medications including anti-cholinergics and protamine 
sulphate with limited temporary success. 
Surgical interventions include cystodistension initially. This intervention 
either does not relieve symptoms or does so temporarily. Unfortunately, 
the ultimate treatment option for these patients with permanent bladder 
damage is either bladder augmentation or urinary diversion procedures in 
the form of ileal conduit or ureterotomy with or without cystectomy. If the 
 20 
patients continue to abuse ketamine after surgical intervention, they risk 
damaging their reservoir and upper renal tracts. 
 
1.2 Non-bacterial cystitis 
Non-bacterial cystitis is a permanent diagnostic dilemma for clinicians and 
includes interstitial cystitis (IC) and eosinophilic cystitis (EC), among other 
conditions. 
 
1.2.1 Interstitial Cystitis 
Interstitial Cystitis (IC) is a debilitating inflammatory disease of the urinary 
bladder which presents with lower urinary tract symptoms (LUTS) and, is 
marked by episodes of flare-ups and remissions. IC is sometimes used 
synonymously with the term Painful Bladder Syndrome (PBS). Whilst PBS 
is a condition of any bladder pain for which an apparent cause is not 
found, IC reflects a subset of PBS and includes patients who meet a strict 
diagnostic criterion established by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK). In a recent meeting by the 
Bladder Pain Syndrome committee of the International Consultation on 
incontinence, it was suggested that IC should be called Bladder Pain 
Syndrome (BPS), as the term is more descriptive of the clinical condition 
(reviewed by [23]). 
There are no definite figures of prevalence for interstitial cystitis and 
different population groups are reported to experience different incidence 
rates. In a review by Kelada et al. [24], the authors suggest that the 
heterogeneous data on the prevalence and incidence of IC is due to a lack 
of uniform diagnostic criteria and universal markers.  
There are different questionnaires in use to screen for IC, including the 
O’Leary-Sant symptom and problem index; the pain, urgency, frequency 
symptom scale; and the University of Wisconsin IC scale. While these 
questionnaires help to distinguish IC from other urinary tract pathologies, 
they do not demonstrate sufficient specificity to serve as the sole 
diagnostic indicator [25]. Differences in interpretation of these 
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questionnaire results may be another reason for varying prevalence data. 
Despite this, almost all studies agree that IC is more prevalent in females. 
 
1.2.1.1 Aetiology of IC 
Despite extensive research of IC, no single aetiological cause has been 
identified. There are multiple theories to explain development of IC with 
limited evidence for each and they include: 
1. Compromised urothelial barrier ([26] and reviewed by [24, 27-29]). 
2. Microbiological ([30] and reviewed by [24, 27, 28, 31, 32]); although 
one of the NIDDK diagnostic criteria for IC is the absence of positive 
urine cultures. Hanno et al. (reviewed in [33]) suggested that the 
reason for this may be that the causative bacteria in IC are fastidious 
or present in small numbers. However, there are studies in literature 
which did not find any infectious agents in patients with IC [34, 35]. 
3. Increased number of mast cells in the bladder wall (reviewed by [27, 
28, 36]); upon activation these degranulate and release pre-formed 
mediators of inflammation such as histamine, heparin and tryptase. 
4. Neurogenic inflammation (reviewed by [24, 31, 32]); according to this 
theory, there are increased number of mast cells at nerve endings in 
the bladder of patients with IC. When triggered these mast cells 
release various vasoactive substances causing inflammation of nerve 
endings in the bladder and symptoms of IC.  
5. Genetic susceptibility to the development of IC [37]. 
6. Abnormal cell signalling pathways (reviewed by [38]); according to 
this theory, there is altered cell signalling in patients with IC resulting 
in altered cell proliferation, differentiation, and tight junction protein 
expression and assembly.  
7. Anti-proliferative factor (reviewed by [38]); according to this theory, 
bladder epithelial cells in patients with IC produce an anti-proliferative 
factor which possibly causes thinning of bladder epithelium, altered 
production of growth factors and increased paracellular permeability 
with decreased tight junction formation. 
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8. Allergic disorder ([39] and reviewed by [27]).  
9. Hormonal factors (reviewed by [24]); it was postulated that the fact 
that most IC patients are women, suggests that the process involving 
mast cells may be hormonally influenced by oestrogens [40]. 
10. Immunological factors or auto-immunity (reviewed by [24, 27, 31, 
32]); the basis for this theory is the increased association of IC with 
certain chronic immunological diseases such as SLE, Scleroderma, 
Fibromyalgia and Sjogren’s syndrome ([41] and reviewed by [28]). 
The patients with IC may have auto-antibodies against mucosal or 
muscle cells, or various other connective tissue components of the 
bladder [41, 42]. Also, there is unexplained association with chronic 
disease or pain syndromes such as irritable bowel syndrome, skin 
sensitivity, vulvodynia, fibromyalgia, migraine, endometriosis and 
chronic fatigue syndrome [43]. 
11. Bladder microvascular damage resulting in decreased microvascular 
density in the suburothelium [44].  
12. Toxic urine components ([26] and reviewed by [28]). 
13. Unidentified agents (reviewed by [24, 31]). 
 
1.2.1.2 Signs/Symptoms of IC 
The common signs/symptoms reported in literature in patients with IC 
include: 
1. Bladder/suprapubic pain ([39, 45] and reviewed by [23, 24, 27, 28, 
31, 32, 46]). Patients usually have a characteristic pain which is 
associated with bladder filling and relieves with voiding. 
2. Chronic pelvic pain (reviewed by [27]). 
3. Dyspareunia (reviewed by [27]). 
4. Urinary frequency ([39, 45] and reviewed by [23, 24, 27, 28, 31, 32, 
46]). 
5. Nocturia ([45] and reviewed by [24, 31, 32]).  
6. Urinary urgency ([45] and reviewed by [23, 24, 27, 28, 31, 32, 39, 
46]).  
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1.2.1.3 Clinical Investigation Findings in IC 
 Radiological investigations: 
There are no specific radiological findings in patients with IC but long 
standing IC may lead to small capacity bladder with upper renal tracts 
involvement. 
 Urodynamics: 
The role of urodynamics in patients with IC is one of excluding other 
diseases. This is because patients with IC do not have any specific 
features demonstrated by urodynamics. 
 Cystoscopy: 
Other than features of inflammation, cystoscopy in patients with IC may 
demonstrate the 2 classical features; 
1. Glomerulations (upon hydrodistension, pinpoint haemorrhages or 
fissures appear in bladder called glomerulations, found more 
frequently than Hunner’s ulcer). 
2. Hunner’s ulcer (found less frequently) at bladder dome (reviewed by 
[27]). 
 Histology: 
There are no definitive diagnostic characteristics or markers for this 
disease (reviewed by [24]) and the role of histopathology in the diagnosis 
of IC is primarily one of excluding other possible pathologies (reviewed by 
[23, 24]).  
Rosamilia et al. [47] reviewed the literature and found epithelial 
denudation or ulceration, mononuclear inflammation, oedema, congestion, 
haemorrhages, and mast cell activation to be the most common findings in 
the histopathology of IC patients. However in the same paper the authors 
suggest that these pathological changes were not universal or specific; 
with 55% of IC subjects in one study having histology that was normal and 
indistinguishable from control subjects (doctoral thesis referred to in [47]). 
The histopathological findings most frequently described in the literature in 
patients with IC are; 
1. Mucosal ulceration/absent mucosa ([48, 49] and reviewed by [50]). 
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2. Submucosal oedema ([44, 51] and reviewed by [50]). 
3. Vasodilatation ([51, 52] and reviewed by [50]). 
4. Mucosal haemorrhage [49]. 
5. Lymphocytic and plasma cell infiltrate [49, 52]. 
6. Submucosal inflammation [48]. 
7. Granulation tissue infiltration [49]. 
8. Increase in mast cells (reviewed by [47]). 
The notable thing about histopathological findings related to IC is that 
almost all of these features possibly reflect chronic tissue damage rather 
than a specific disease process i.e. late stage damage and, reaction to 
loss of urothelial barrier and chronic exposure to urine.  
 Immunohistochemistry: 
1. From a study published by Southgate et al. [53], the results of 
immunohistochemistry studies performed on areas of full thickness 
urothelial samples from patients with IC and urothelium from patients 
with other benign conditions (idiopathic detrusor over-activity and 
stress urinary incontinence) indicated no gross difference, with the 
possible exception of Claudin 5 down-regulation in one IC specimen.  
2. There is also little evidence of proliferation being driven in situ in IC 
specimens, as seen from the lack of Ki67 positive cells by 
immunohistochemistry [53]. 
 
1.2.1.4 Management of IC 
Management of patients with IC is an on-going challenge for clinicians. As 
mentioned before, most of these patients are diagnosed late after 
excluding other diseases due to the lack of objective specific biomarkers. 
This means that most of these patients have irreversible bladder damage 
by the time of diagnosis and are quite difficult to manage. 
The conservative treatment includes advising patients about life style 
changes including fluid management. Medical treatment mainly includes 
analgesics and anti-cholinergics. If all else fails, surgery in the form of 
bladder augmentation or urinary diversion procedures is offered. 
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1.2.2 Eosinophilic Cystitis (EC) 
Eosinophilic cystitis (EC) is a relatively uncommon inflammatory disease of 
the urinary tract. It is characterised by the presence of troublesome lower 
urinary tract symptoms and eosinophilic infiltration of involved urinary 
bladder tissue. Although patients with EC present with non-bacterial 
cystitis symptoms similar to IC, it is a distinct clinical disease.  
In a review article in 2009, Ebel Sepulveda et al. reported that there are 
less than 200 reported cases of EC in the world [54]. EC has been 
reported at all ages (5 days to 87 years), with 21% of cases occurring in 
children in one series [55]. There are differing literature reports about its 
incidence among adult males and females. Popescu et al. [56] suggested 
in their case series and literature review that EC is more common in 
females (in adult population) and that the equal sex incidence reported by 
Itano et al.  [57] and Van Den Ouden et al. [55] actually reflects study 
group composition rather than actual incidence rates. In children, boys are 
affected more often than girls [55]. 
 
1.2.2.1 Aetiology of EC 
Although different theories have been proposed to explain the 
aetiopathology, there is no conclusive evidence for a single cause. These 
include: 
1. Allergy due to food [58].  
2. Allergy to iodine, anaesthetic ointments, condom antigens or 
contraceptive jellies [59].  
3. Allergy to chromated catgut suture [60]. 
4. Immunological factors (reviewed by [54]). 
5. Parasitic infestation of bladder [61-63]. 
6. Medications including salicylazosulfapyridine, tranilast, coumadin, 
intravesical thiotepa and mytomycin ([64-66] and reviewed by [67, 
68]). 
7. Prostatic hyperplasia, and surgeries or tumours of the bladder and 
prostate ([55] and reviewed by [69-71]).  
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1.2.2.2 Signs/Symptoms of EC 
The following signs and symptoms due to EC have been reported in the 
literature; 
1. Suprapubic/abdominal pain ([72] and reviewed by [55, 56]). 
2. Dysuria (reviewed by [55, 56]). 
3. Macroscopic/microscopic haematuria ([72] and reviewed by [55, 56]). 
4. Urinary frequency ([72] and reviewed by [55, 56]). 
5. Urinary urgency ([72] and reviewed by [56]). 
6. Urge incontinence (reviewed by [56]). 
7. Less commonly; urinary retention (reviewed by [55, 56]), 
gastrointestinal symptoms such as vomiting, diarrhea, tenesmus 
(feeling of incomplete evacuation) and bloody stools, fever, skin rash, 
pneumaturia and nocturnal enuresis (reviewed by [56]). 
 
1.2.2.3 Clinical investigation findings in EC 
 Radiological investigations: 
The radiological investigations might show; 
1. Bladder tumour associated with EC [72]. 
2. Less commonly upper renal tract involvement (in 1 out of 8 patients 
reported by Lin et al. [73] and in 1 out of 17 cases reported by Itano 
et al. [57]). 
 Urodynamics: 
The role of urodynamics in patients with EC (similar to IC) is to exclude 
other diagnosis. 
 Cystoscopy: 
1. In most cases, cystoscopy shows oedematous bladder mucosa ([73] 
and reviewed by [56]). 
2. It might also show bladder tumour associated with EC [72]. 
 Histology:  
1. Bladder biopsy of involved tissue in EC characteriscally demonstrates 
eosinophilic infiltration ([72] and reviewed by [74, 75]). Lower urinary 
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tract symptoms with histology demonstrating eosinophilic infiltration 
of the bladder tissue are the gold standard for diagnosing EC. 
2. Mast cells and plasma cells in chronic phase [76]. 
 Immunohistochemistry: 
There are no literature reports to date of immunohistochemistry studies on 
EC tissue. 
 
1.2.2.4 Management of EC 
There is no definitive treatment regime for patients with EC. Eosinophilic 
infiltration of the biopsy specimen is one of the main diagnostic criterion 
and eosinophils are known to be associated with allergy. The conservative 
treatment strategy is therefore based on avoiding exposure to any 
allergens and treatment with antihistamines. Steroids and antibiotics have 
been tried as a medical treatment with limited success. Surgical options 
include removal of bladder tumour which may be the cause of symptoms 
as proposed by Verhagen et al. [72], bladder augmentation procedures or 
urinary diversion procedures. 
 
1.3 Discussion 
The gap in knowledge about the aetiology of IC and EC has meant that no 
effective research models have been developed and neither can we 
develop any specific biomarkers for clinical diagnosis. This has eventually 
translated in to the inability to develop any effective treatment regimens for 
either condition. 
Most models to study IC have been based on inducing acute urothelial 
damage by treatment with drugs such as cyclophosphamide [77]. In a 
recent article by Altuntas et al., authors have described a method of 
inducing autoimmune cystitis in an animal (mice) model over a period of 
weeks by immunization of mice with recombinant mouse uroplakin II 
(rmUPK2) [78]. This is different and a better IC experimental animal model 
than the previous ones based on drug-induced cystitis in that 
cyclophosphamide induces cystitis within hours and is not as such 
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representative of the disease as IC is a chronic inflammatory condition 
which develops overs months to years.  
Ketamine causes urinary tract damage in patients over months to years 
and the course of development of KIC is much similar to IC. Clinical 
presentation in patients with KIC, IC and EC is with lower urinary tract 
symptoms. KIC as the cause of patient’s symptoms is only indicative once 
a drug history of ketamine use/abuse is given by the patient.  
Another condition where a history of ketamine use/abuse is of utmost 
importance is in patients with suspected carcinoma in situ (CIS) of the 
bladder. CIS is a flat, non-invasive but high grade cancerous lesion which 
is confined to the superficial lining of the bladder. Unlike most other CIS, 
bladder CIS is fairly aggressive and urine samples in almost 90% of the 
patients demonstrate malignant cells. Patients with this condition present 
with LUTS similar to the patients with KIC. Oxley et. al. conducted an 
immunohistological study on 10 KIC biopsies and reported that patients 
with both KIC and CIS demonstrated nuclear enlargement and 
disorganisation but the patients with KIC were negative for CK20 staining 
suggesting reactive atypia only and no CIS [16]. Whether chronic 
inflammation from ketamine use/abuse would eventually lead to the 
development of bladder cancer or not is currently unknown as KIC is a 
relatively new condition and no long term follow-up studies exist. 
The clinical and investigation similarities between KIC, IC and EC may 
mean that the mechanisms behind development of these conditions are 
similar in some respect as well. If this is true, it will further mean that 
understanding the mechanism of disease development in one illness may 
give an insight in to the mechanisms of development of disease in the 
other condition. KIC can be used as a model for this purpose and although 
the mechanisms of disease development in KIC are unknown at present, 
the benefit in using KIC as a research model will be that the causative 
agent is known. 
There are established procedures to grow normal human urothelial (NHU) 
cells in vitro [79] and these can be used to investigate the possible 
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mechanisms of disease development in patients with KIC. The advantage 
in using NHU cells will be that they are not compromised by the in vitro 
propagation and retain the capacity to contribute to a functional epithelium 
[79]. This method will therefore provide an adequate model to conduct the 
research project as an in vivo study involving patients may not be possible 
due to the ethical constraints associated with knowingly giving someone 
ketamine to cause urinary tract damage. 
 
1.4 Aims 
1. Primary aim of the research was to examine potential mechanisms 
behind development of ketamine-induced human urinary tract 
damage. 
2. Secondary aim of the research was to investigate potential links 
between ketamine-induced cystitis, interstitial cystitis and eosinophilic 
cystitis. 
 
1.5 Objectives 
1. To establish the toxic doses of ketamine for normal human urothelial 
(NHU) cells grown in culture. 
2. To establish whether ketamine or its primary metabolite nor-ketamine 
is the main toxic agent. 
3. To establish whether there is a dose response relationship between 
ketamine and NHU cell damage. 
4. To assess whether the NMDA antagonist effect of ketamine is 
responsible for human urothelial cell toxicity. 
5. To describe urothelial damage caused by ketamine by assessing 
proliferation, differentiation and inflammatory changes in human KIC 
tissue. 
6. To investigate clinically a possible relationship between analgesic 
ketamine use and development of KIC symptoms.   
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2 Materials and Methods 
The research on samples from ketamine users was approved by the 
Northern and Yorkshire research ethics committee (REC reference 
number 10/H0903/43).  
It was a multicentre study and appropriate Research and Development 
(R&D) approval and material transfer agreement (MTA) was additionally 
obtained at each site before transporting the tissue to the Jack Birch Unit 
of Molecular Carcinogenesis, Department of Biology, University of York 
where all the experiments were carried out. 
The NHS trusts participating in this study were; 
1. James Cook University Hospital, Middlesbrough (R&D reference No. 
2010081) 
2. Southmead Hospital, Bristol (R&D reference No. 2537) 
All the tissue samples were taken after full informed patient consent. 
Samples were encoded with a research number and patient confidentiality 
was maintained at all stages of the research. 
All cell biology experiments were performed on normal human urothelial 
(NHU) cells isolated from normal (non-KIC) tissues under a different REC 
approval and grown as finite cell lines in culture by seeding in to Primaria 
tissue culture flasks using established procedures [79]. Cells were seeded 
in known numbers in 96-well plates, treated with different concentrations 
of drugs (ketamine, nor-ketamine and/or MK-801) as required for the 
experiment and plates were kept in a humidified incubator at 37ºC in 5% 
CO2 in air. Cell biomass was assessed using Alamar blue (AB) assay.  
Ketamine used for the experiments was racemic, stable and had >99% 
purity as tested by thin layer chromatography. The purity of nor-ketamine 
was 100% and that of MK-801 was >99% as tested by high performance 
liquid chromatography (HPLC). Both nor-ketamine and MK-801 were 
stable at room temperature. Hydrogen-1 nuclear magnetic resonance   
(1H NMR) testing showed that both nor-ketamine and MK-801 were 
consistent with their structures (information from the manufacturer’s 
websites; Sigma-Aldrich and Tocris). 
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All immunohistochemistry experiments were performed on formalin-fixed 
and paraffin wax-embedded tissues, and included control (positive and 
negative) slides.  
Unless otherwise stated, all the cell biology and immunohistochemistry 
experiments were performed using the protocols detailed below. 
 
2.1 Cell Biology 
2.1.1 Passaging cells 
1. Medium was carefully aspirated from the flask containing the 
adherent cell culture and 10ml of pre-warmed sterile EDTA (0.1% 
(w/v) in PBS) was added. The flask was placed in an incubator at 
37C until cells had rounded.  
2. EDTA was aspirated off and one ml of TV was added to the flask, 
and rocked gently to ensure that the surface was covered. The flask 
was then placed back in the incubator at 37C until cells had become 
mobile/lifted (flask was tapped outside the incubator if required to 
add mobilising/lifting of cells).  
3. TI was prepared by adding 10ml of sterile KSFMC to one aliquot of TI 
and added to the flask. The solution was gently passed through the 
pipette several times to ensure a single cell suspension.  
4. The suspension was then transferred in to a universal tube and 
centrifuged at 1500rpm for four minutes.  
5. After centrifugation, supernatant was removed and the pellet was 
flicked to suspend.  
6. KSFMC was added by gently pipetting up and down. Cells from one 
100% confluent T75 flask were passaged in to two to three T75 
flasks as per requirement for the experiment.  
7. Flasks were then kept in a humidified incubator at 37C and 5% CO2 
in air, in a tray cleaned with 70% ethanol. Medium was changed 
every two to three days. 
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2.1.2 Freezing cells 
1. Cells were passaged up to step five as described above in section 
2.1.1.  
2. Freezing mix was added by gently pipetting up and down.  
3. Cryo vials were labelled using a JBU number, date, cell line and 
passage number.  
4. One ml of cell suspension was placed in each cryo vial.  
5. The cells were then frozen by keeping them in the isopropanol box at 
-80C overnight and then transferring to liquid nitrogen dewar for 
storage.  
6. Cells from one 95-100% confluent T75 flask were frozen down in to 
three cryo vials. 
 
2.1.3 Bringing cells up from freezing 
1. The required cells were located from the initial stock reference book.  
2. 10ml of pre-warmed KSFMC was placed in a universal container. 
3. One T75 flask was labelled with date, cell type (NHU cells), passage 
number (one + the passage number at which cells were frozen) and 
my initials.  
4. Cryovial was removed from the liquid nitrogen dewar and thawed 
under warm water to defrost.  
5. One ml cell suspension from the vial was transferred to the universal 
container and the vial was rinsed with medium to ensure all cells 
were removed.  
6. The universal was centrifuged at 1500rpm for four minutes.  
7. The supernatant was carefully removed and the pellet was flicked to 
suspend.  
8. Five ml of KSFMC was added by gently pipetting up and down.  
9. Cells were transferred in to the T75 flask and further 10ml of KSFMC 
was added to the flask to make a total volume of 15ml.  
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10. The flask was placed in a humidified incubator at 37C and 5% CO2 
in air, in a tray cleaned with 70% ethanol. Medium was changed 
every two to three days. 
 
2.1.4 Cell counting using the improved Neubauer 
haemocytometer 
1. Cells were passaged up to step five as described above in section 
2.1.1.  
2. After centrifugation, supernatant was removed and the pellet was 
flicked to suspend.  
3. 10ml of KSFMC was added by gently pipetting up and down to 
ensure good cell suspension in the medium. 
4. Improved Neubauer haemocytometer and a cover slip were cleaned 
with 70% ethanol and dried. Upper surface of the haemocytometer 
was moistened by breathing to produce a film of water vapour and 
cover slip was pressed into the haemocytometer.  
5. A drop of cell suspension was placed against the edge of the cover 
slip in the middle of the chamber using a pipette.  
6. The haemocytometer was placed under a microscope and focussed 
on the grid.  
7. Total number of cells in the four outer squares were counted and 
divided by four. The resulting number represented the number of 
cells in 0.0001ml medium 
 
2.1.5 Preparing 96-well plates 
1. Once cell number/ml was established as described above in section 
2.1.4, the cell suspension was further diluted using KSFMC to obtain 
optimum cell concentration for the experiment.  
2. 0.2ml of the pre-determined cell concentration was put in each well of 
a 96-well plate with 0.2ml sterile water in the wells around them to 
keep cells hydrated and plates were placed in a humidified incubator 
at 37C and 5% CO2 in air for further experiments as planned. 
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2.1.6 Cell biomass assay 
1. Alamar blue (AB) dye was prepared by diluting the dye 1:10 ratio with 
KSFMC (e.g. 10ml alamar blue dye prepared by mixing one ml AB 
with nine ml KSFMC).  
2. To check cell viability, an appropriate quantity of AB dye was 
prepared.  
3. 96-well plates were removed from the incubator and medium in the 
plates was removed by turning them upside down and shaking.  
4. 0.2ml of prepared AB dye was put in each well with cells and also in 
one column without cells for reference.  
5. 0.2ml sterile water was put in the wells around the AB treated wells 
to keep cells hydrated and plates were placed in a humidified 
incubator at 37C and 5% CO2 in air.  
6. The plates were then read after four hours using the ascent software 
previously calibrated to establish number of viable cells using the 
equation below [80]; 
1-21 x a3x8886 = b (where a = Alamar blue reduction and b = cell 
number). 
 
2.2 Immunohistochemistry 
2.2.1 Formalin fixation of tissues for paraffin wax embedding 
1. Tissue samples were dissected to appropriate size in a Petri dish 
using a fresh scalpel (if needed).  
2. Samples were placed into 10% (v/v) formalin in a labelled universal 
tube ensuring the samples were fully immersed with at least a three 
cm depth of formalin above the sample and incubated at ambient 
temperature for: 
 
Sample Size Fixation Period 
<1cm3 18 hours 
1-3cm3 48 - 72 hours 
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3. After fixation, formalin was replaced with the same volume of fresh 
70% ethanol and the fixed tissue was stored until processed into 
paraffin wax.   
 
2.2.2 Paraffin wax embedding of tissue specimens  
1. Embedding cassettes were appropriately labelled and tissue was 
placed in them.  
2. The cassettes were submerged in fresh 70% ethanol for 10 minutes 
on a shaker.  
3. Cassettes were placed in absolute ethanol for 10 minutes on the 
shaker and repeated a further two times.  
4. The cassettes were moved in to fresh isopropanol for 10 minutes on 
the shaker and repeated once.  
5. The cassettes were put in fresh xylene for 10 minutes and repeated a 
further three times. Cassettes were taken out of xylene and excess 
xylene was removed by blotting thoroughly with a tissue.  
6. The cassettes were put in four wax pots for 15 minutes each in the 
incubator at 55oC.  
7. Tissue samples were then embedded in paraffin wax in the cassettes 
using moulds and left on the cool table to set.  
8. Once the tissue had set in the wax, it was stored in a cool dry place.  
 
2.2.3 Sectioning of paraffin wax-embedded tissue 
1. Cassettes were left on cool table for about 30 minutes to 1 hour 
before sectioning.  
2. Glass slides were labelled with appropriate tissue details.  
3. A Leica RM2135 Microtome was used to cut tissue sections of five 
micron thickness 
4. Sections were put in pre-warmed tissue flotation bath.  
5. Sections were picked up on to the glass slides and left to air dry 
overnight. 
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2.2.4 Haematoxylin and Eosin staining of tissue sections 
1. Labelled glass slides with tissue sections were placed on a pre-
warmed slide heater for one hour and then air dried for 10 minutes. 
2. Sections were de-waxed by placing slides sequentially in to; two 
xylene pots for 10 minutes each, two xylene pots for one minute 
each, three pots containing absolute ethanol for one minute each and 
finally a pot containing 70% ethanol for one minute.  
3. The slides were washed under running tap water for one minute and 
placed in haematoxylin for one minute.  
4. Slide rack was placed under running tap water for one minute and 
placed in Scott’s tap water for one minute.  
5. The slides were washed in running tap water for one minute and 
placed in eosin for 30 seconds.  
6. The slides were washed in running tap water for the last time for one 
minute.  
7. The tissue sections were re-hydrated by placing slides sequentially in 
to; a pot containing 70% ethanol for one minute, three pots 
containing absolute ethanol for one minute each and finally in to two 
pots containing xylene for one minute each.  
8. The slides were then placed in to two pots of histoclear for 15 
seconds each.  
9. The tissue sections were mounted in DPX using cover slips and left 
to air dry overnight. 
 
2.2.5 Antigen retrieval methods for immunoperoxidase 
experiments 
Microwave (Citric Acid)  
1. Slides were placed in 350ml of 10mM Citric Acid Buffer pH 6.0 in a 
pyrex dish and glass marbles were placed on each end of glass slide 
to keep it in place.  
2. The dish was covered with cling film and holes were punched in the 
film to let steam out.  
 37 
3. The dish was placed in a microwave for 13 minutes at full power and 
then placed on ice to cool down when finished. 
Trypsinisation 
1. 100ml of 0.1%CaCl2 pH 7.8 was warmed to 37C in the microwave. 
2. 0.1g of trypsin was added to it and mixed thoroughly to dissolve the 
trypsin completely.  
3. Slides were incubated in this 0.1% trypsin solution (w/v) in an 
incubator at 37C for 10 minutes.  
Trypsin and Microwave  
1. 100ml of 0.1%CaCl2 pH 7.8 was warmed to 37C in the microwave. 
2. 0.1g of trypsin was added to it and mixed thoroughly to dissolve the 
trypsin completely.  
3. Slides were incubated in this 0.1% trypsin solution (w/v) in an 
incubator at 37C for one minute and then microwaved in 10mM 
Citric Acid Buffer pH 6.0 for 13 minutes as described above.  
 
2.2.6 Immunoperoxidase on Paraffin sections 
1. Tissue sections were de-waxed as described above in section 2.2.4. 
2. The slides were washed under running tap water for one minute and 
placed in100ml of 3% H2O2 for 10 minutes.  
3. The slides were washed under running tap water for 10 minutes. 
4. Depending on the manufacturer’s recommendations for the antibody 
used, one of the antigen retrieval methods as described in section 
2.2.5 was used.  
5. The slides were washed in running tap water for one minute.  
6. The slides were then placed in Shandon Sequenza using coverplates 
and the tissue sections were incubated at ambient temperature 
sequentially in;  
a) 100µl of Avidin for 10 minutes.  
b) Washed twice with TBS.  
c) 100µl of Biotin for 10 minutes.  
d) Washed twice with TBS.  
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e) 100µl of appropriate serum (normal rabbit serum for mouse primary 
antibody and normal goat serum for rabbit primary antibody) diluted 
1:10 with TBS for five minutes.  
f) 100µl of primary antibody at a predetermined dilution in TBS applied 
to positive slides and 100µl of TBS to negative slides for one hour.  
g) Washed three times with TBS.  
h) 100µl of biotinylated secondary antibody at a predetermined dilution 
in TBS dependant on the primary antibody (biotinylated rabbit anti 
mouse secondary antibody for mouse primary antibody and 
biotinylated goat anti rabbit secondary antibody for rabbit primary 
antibody) for 30 minutes.  
i) Washed twice with TBS. 
j) StrepAB/HRP complex prepared by mixing one drop of A and one 
drop of B (from Vectastain elite ABC kit) with 2.5ml TBS atleast 30 
minutes before applying and 100µl applied to each slide for 30 
minutes. 
k) Washed twice with TBS and once with distilled water.  
l) DAB solution prepared by mixing sigma fast DAB tablets with five ml 
of TBS thoroughly and 200µl of DAB solution applied to each slide for 
15 minutes.  
m) Slides were washed twice with distilled water and immediately placed 
in the staining rack.  
7. Counterstaining was done in Mayer’s haematoxylin solution (Sigma) 
for 10 seconds. 
8. The slides were washed for one minute in running tap water. 
9. Tissue sections were then re-hydrated and mounted in DPX as 
described above in section 2.2.4.  
Visualization of low-expression targets (e.g. NGFR) was enhanced by use 
of the catalytic signal amplification (CSA) kit as recommended by the 
manufacturer (Dako). 
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2.2.7 Alcian Blue – Periodic Acid Schiff (AB-PAS) with diastase 
digestion staining 
1. Tissue sections were de-waxed as described above in section 2.2.4. 
2. The slides were washed under running tap water for one minute. 
3. The slide rack was placed in Alcian Blue solution for 10 minutes.  
4. The slides were washed in running tap water for one minute first and 
then rinsed once in distilled water. 
5. One gram of diastase was dissolved thoroughly in 100ml of 
deionised (ELGA) water in a glass slide rack and slides were placed 
in it.  
6. The glass slide rack was placed in a microwave at 600 watts for 25 
seconds and washed in running tap water for five minutes. 
7. The slides were immersed in Periodic Acid solution for five minutes 
at ambient temperature and rinsed in three changes of distilled water. 
8. The slides were immersed in Schiff’s reagent for 15 minutes at 
ambient temperature and washed in running tap water for five 
minutes. 
9. The slides were counterstained in haematoxylin solution for 90 
seconds and washed in running tap water for one minute to remove 
excess haematoxylin. 
10. The tissue sections were re-hydrated and mounted in DPX as 
described above in section 2.2.4.  
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3 Establishing in vitro toxicity of ketamine 
 
3.1 Introduction 
Ketamine-induced cystitis (KIC) is a relatively new condition and although 
the causative agent in patients with KIC is known, the pathological 
mechanism of disease development remains unknown. Chu et al. 
suggested that it may either be from ketamine or its metabolites via either 
a direct effect or microvascular damage or an autoimmune reaction [2]. 
The lack of knowledge about mechanism of KIC development means that 
no effective treatment strategies can be developed for these patients to 
either block or treat the urinary side effects.  
As patients using therapeutic ketamine may be at risk of urinary tract 
damage as well, one solution can be to take them off ketamine and try 
them on other treatments which may not be as effective. A better 
approach will be to keep these patients on ketamine and at the same time 
try to understand and ameliorate the mechanisms of human urinary tract 
damage by this drug so that they may long benefit from their symptoms 
relief without suffering the urinary side effects. 
Mechanisms of KIC development are not understood at present but may 
be via one or both of the following pathways; 
1. Direct interaction of ketamine and its metabolite nor-ketamine with 
the urothelium causing damage to the urothelial barrier function and 
consequent development of KIC. This hypothesis is based on the fact 
that both ketamine and nor-ketamine are excreted by urine and have 
a long duration (ketamine 5 days, nor-ketamine 6 days) of direct 
contact with urothelium after ingestion [81]. 
2. Receptor mediated urothelial cell toxicity. This hypothesis is based 
on the reports of neuronal toxicity in animal cell cultures via NMDA 
receptor antagonist effect [82, 83]. 
To test the above hypotheses, an in vitro experimental approach was 
undertaken. 
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3.2 Aim 
To investigate toxicity of ketamine and its primary metabolite nor-ketamine 
on normal human urothelial (NHU) cell cultures. 
 
3.3 Objectives 
Objective 1: While the accepted human anaesthetic dose of ketamine is 
0.5-2 mg/kg, there is no general consensus in literature to suggest a 
concentration where there will be definite urinary tract damage. Compared 
to the high concentrations of ketamine abused (up to 20 g/day) (reviewed 
by [8]), there are literature reports of human urothelium damage from 
ketamine use as an analgesic in much lower concentrations (up to 1 
g/day) [3, 14]. The first objective therefore was to establish the toxic 
concentrations of ketamine for NHU cells. 
 
Objective 2: Once ingested, ketamine is metabolised by the liver to nor-
ketamine (primary metabolite) and is excreted in urine [81]. After ingesting 
ketamine, it can be found in urine for up to 5 days and as nor-ketamine for 
up to 6 days [81]. As suggested by Chu et al., the development of KIC 
may be via different mechanisms involving ketamine and/or its metabolites 
[2]. It is therefore important to establish whether nor-ketamine is toxic to 
NHU cells as it may contribute to the effects of ketamine. Furthermore, as 
nor-ketamine stays longer in urine as compared to ketamine, it is possible 
that if toxic, it causes more damage to NHU cells. The second objective 
therefore was to establish whether ketamine or nor-ketamine is the main 
toxic agent. 
 
Objective 3: Another interesting observation to emerge from the 
literature review is that although ketamine abuse is on the rise (reviewed 
by [8, 12]), the number of patients presenting with KIC is not. The reason 
for this may be that as it is the party goers who are increasingly using 
ketamine (reviewed by [8]) and they only use it occasionally, the high 
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regenerative and proliferative ability of urothelium helps it repair itself 
between doses after the initial damage. This means that although 
occasional abusers of ketamine get temporary symptoms, they usually 
resolve as the urothelium recovers. However if the ketamine insult to 
human urothelium is regular, it might not have the chance to repair itself. 
The damage would eventually become permanent and the symptoms 
irreversible. The third objective therefore was to establish whether daily 
ketamine use is more toxic to NHU cells as compared to a single dose. 
 
Objective 4: Although ketamine is used for its NMDA receptor antagonist 
properties in clinical practice, it is reported to have promiscuous effects on 
multiple other receptor sites as well (reviewed by [9]). Literature reports in 
animal models suggest that the NMDA antagonist activity of ketamine is 
responsible for neuronal toxicity [82, 83]. It is therefore possible that either 
the same receptor or any of the other receptors ketamine acts on are 
responsible for human urothelial toxicity as well. The fourth objective 
therefore was to examine whether the NMDA antagonist effect of ketamine 
is responsible for human urothelial cell toxicity. 
 
3.4 Experimental approach 
To plot a standard curve for future cell biology experiments, two T75 flasks 
of 100% confluent NHU cells (Cell line Y1071, P3) were harvested and re-
suspended in KSFMC to make a final cell concentration of 50 x 104 
cells/ml. Different cell concentration solutions including 1.25 x 104 cells/ml, 
2.5 x 104 cells/ml, 3.75 x 104 cells/ml, 5 x 104 cells/ml, 12.5 x 104 cells/ml, 
25 x 104 cells/ml, 37.5 x 104 cells/ml and 50 x 104 cells/ml were prepared. 
0.2ml of each cell concentration solution was seeded in to six wells of a 
column of one 96-well plate. 0.2ml of sterile water was placed in the wells 
around the wells with cells to keep them hydrated and the plate was 
placed in a humidified incubator at 37C and 5% CO2 in air for 90 minutes. 
Cells were then treated with Alamar blue dye and the plate was placed 
back in the incubator with sterile water in the wells around Alamar blue 
 43 
y = 7E-30x5.1479 
R² = 0.9882 
0
20000
40000
60000
80000
100000
120000
1900000 2900000 3900000 4900000
C
e
ll
 n
u
m
b
e
r 
Alamar blue reduction 
treated cells to keep them hydrated. The plate was removed after four 
hours from the incubator and read using Ascent software. The results 
were then charted on a graph (figure 3.1) to generate a standard formula 
for future cell biomass assay using Alamar blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All further experiments were performed after seeding NHU cells in known 
numbers in 96-well plates, treating with different drugs as appropriate for 
the experiment and assessing cell viability by using Alamar blue cell 
biomass assay (as described in Chapter 2). The results from the Alamar 
blue assay were converted in to cell numbers using the above formula.  
Statistical analysis was done using the InStat3 software. An Unpaired t-
test was used to statistically analyse two sets of cell numbers and one way 
ANOVA test was used for analysing more than two sets of cell numbers.  
P values of <0.001 were considered as extremely significant (***), 
<0.01as highly significant (**), <0.05 as significant (*) and >0.05 as not 
significant (ns). 
Figure 3.1: Alamar blue reduction by different numbers of NHU cells   
(n=6, Error bars = Standard Deviation) plotted on a graph to generate a 
standard formula for future cell biomass assay experiments using Alamar 
blue. Formula: y = 7E-30x5.1479, R2 value of the chart 0.9882. 
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Objective 1: Experiments were performed to establish the in vitro toxic 
concentrations of ketamine for NHU cells.  
Experiment 1: Two T75 flasks of 80% confluent NHU cells (cell line 
Y1071, P4) were harvested and re-suspended in KSFMC to achieve a 
final cell concentration of 2x104 cells/ml. Cells were seeded in to four 96-
well plates to prepare one control and three plates for ketamine treatment.  
For the control plate, cells were seeded in to six wells of one column. For 
the three 96-well plates to be used for establishing toxic concentrations of 
ketamine, cells were seeded in to six wells of 11 columns in each of the 
three plates.  
Alamar blue assay was performed on the control plate next day (day 0) 
and NHU cells in the other three plates were treated with different doses of 
ketamine ranging from 0 to 10mM. Alamar blue assay of ketamine treated 
96-well plates was performed on days one, two and five. 
Experiment 2: For establishing toxicity of ketamine at concentrations 
below 1.0mM, a second experiment was performed. One T75 flask of NHU 
cells (cell line Y588, P4) was harvested and re-suspended in KSFMC to 
achieve a final cell concentration of 2x104 cells/ml. Cells were seeded in to 
five 96-well plates to prepare one control and four plates for ketamine 
treatment.  
For the control plate, cells were seeded in to six wells of one column. For 
the four 96-well plates to be used for examining toxicity of ketamine below 
1mM doses, cells were seeded in to six wells of six columns in each of the 
four plates. 
Alamar blue assay was performed on the control plate next day (day 0) 
and the other four plates were treated with different doses of ketamine 
ranging from 0 to 1.2mM. Alamar blue assay of ketamine treated 96-well 
plates was performed on days two, five, six and seven with medium 
change in the remaining three plates on day two. 
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Objective 2: To compare the toxicity of nor-ketamine and ketamine, two 
T75 flasks of 60% confluent NHU cells (cell line Y1072, P4) were 
harvested and re-suspended in KSFMC to achieve a final cell 
concentration of 3x104 cells/ml. Cells were seeded in to nine 96-well plates 
to prepare one control and eight plates for ketamine and nor-ketamine 
experiment. 
For the control plate, cells were seeded in to six wells of one column. For 
the eight 96-well plates to be used for establishing toxicity difference of 
ketamine and nor-ketamine, cells were seeded in to six wells of six 
columns in each of the nine plates. 
Alamar blue assay of the control plate was performed after 48 hours (day 
0). The other eight 96-well plates were divided in to two sets of four and 
the NHU cells in those plates were treated with different doses of ketamine 
and nor-ketamine which were same for both. Alamar blue assay was 
performed on one plate from each set on days three, four, five and seven 
with medium change in the remaining two plates from each set on day 
four. 
 
Objective 3: To assess whether daily ketamine use was more toxic to 
NHU cells than a single dose, three T75 flasks of 70% confluent NHU cells 
(cell line Y1072, P4) were harvested and re-suspended in KSFMC to 
achieve a final cell concentration of 3x104 cells/ml. Cells were seeded in to 
10 x 96-well plates to prepare one control and nine plates for ketamine 
treatment.  
For the control plate, cells were seeded in to eight wells of one column. 
For the nine 96-well plates to be used for daily versus single ketamine 
treatment experiment, cells were seeded in to eight wells of five columns 
in each of the nine plates. 
Alamar blue assay of the control plate was performed after 72 hours (day 
0). The other nine 96-well plates were treated with different concentrations 
of ketamine ranging from 0 to 1.2mM. One plate was selected at random 
to perform Alamar blue assay next day and results used as day one for 
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data analysis. The other eight plates were divided in to two sets of four. 
One set of plates were labelled as single treatment and had no further 
medium change. Four plates in the other set were labelled as daily 
treatment and had medium changed daily. Alamar blue assay was 
performed on one plate from each set on days two, three, four and five.  
Highest and lowest cell numbers from each column were removed from all 
96-well plate results to reduce standard deviation. Day three results were 
not included in the final analysis due to erroneous nature of the data. 
 
Objective 4: Using MK-801 as a specific NMDA receptor antagonist, 
work by colleagues done at the Jack Birch Unit of Molecular 
Carcinogenesis at the University of York showed that NMDA antagonist 
effect of ketamine was not responsible for NHU cell damage [84]. 
However, correspondence from Pfizer indicated that although MK-801 
(specific NMDA antagonist) itself had no effect on urothelial cells in animal 
cultures, it enhanced the toxic effect of ketamine when used in 
combination. 
To test the above in NHU cells, the following experiment was performed. 
Four T75 flasks of 60-70% confluent NHU cells (cell line Y1072, P5) were 
harvested and re-suspended in KSFMC to achieve a final cell 
concentration of 3x104 cells/ml. Cells were seeded in to seven 96-well 
plates to prepare one control and six plates for ketamine and MK-801 
treatment.  
For the control plate, cells were seeded in to eight wells of one column. 
For the six 96-well plates to be used for ketamine and MK-801 experiment, 
cells were seeded in to eight wells of 10 columns in each of the six plates. 
Alamar blue assay of the control plate was performed after 72 hours (day 
0). In the other six plates, cells in one column had no drug treatment 
(control column), cells in one column were treated with MK-801 at a 
concentration of 100µM, cells in four columns were treated with ketamine 
alone in doses of 0.4, 0.6, 0.8 and 1.0mM, and cells in the other four 
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columns were treated with a combination of ketamine (doses of 0.4, 0.6, 
0.8 and 1.0mM) and MK-801 at 100µM concentration. 
Alamar blue assay was performed on treatment plates on days one, two, 
four, seven, eight and nine with medium change in the remaining plates on 
days two, four and seven.  
Highest and lowest cell numbers from each column were removed from all 
96-well plate results to reduce standard deviation. 
 
3.5 Results 
Objective 1 (Experiments 1 and 2): Treatment of known number of 
NHU cells seeded in 96-well plates with different concentrations of 
ketamine showed that it was cytostatic and had a concentration 
dependent-effect which increased as the dose of ketamine was increased. 
Although all concentrations of ketamine were cytostatic, there was no 
statistically significant difference in toxicity between different 
concentrations above 1mM (figures 3.2, 3.3 and 3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Experiment 1; NHU cells treated with 0 - 10mM ketamine showed 
that it was cytostatic at all concentrations (day 5, n=5-6, p<0.001,                
Error bars = Standard Deviation). Although there was some increase in cell 
number at lower doses (1 - 4mM) initially, the cell growth stopped eventually at 
all concentrations by day 5. Statistical analysis shown is between control and 
1mM ketamine concentration at day 5. 
*** 
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Figure 3.4: Experiment 2; NHU cells treated with 0 - 1.2mM ketamine showed 
that it was toxic to NHU cells at concentrations of 0.4mM and above from day 6 
onwards (n=6, p<0.001, Error bars = Standard Deviation). Statistical analysis 
shown is between control and 0.4mM ketamine concentration at day 7. 0.1mM 
ketamine concentration did not show NHU cell toxicity but this result may be 
limited by the duration of experiment (7 days). 
 
Figure 3.3 (data extracted from figure 3.2): Experiment 1; NHU cells treated 
with 0 - 10mM ketamine showed that ketamine was cytostatic at all 
concentrations when compared to control (day 5, n=5-6, p<0.001,               
Error bars = Standard Deviation) but the toxicity difference between different 
ketamine concentrations (1-10mM) was statistically not significant (day 5,    
n=5-6, p>0.05, Error bars = Standard Deviation).  
 
ns 
*** 
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Figure 3.6: NHU cells treated with 0.5 – 6mM nor-ketamine showed statistically 
significant toxicity difference to control at concentrations of 0.5mM and above 
(n=6, p<0.001, Error bars = Standard Deviation). 
Figure 3.5: NHU cells treated with 0.5 – 6mM ketamine showed statistically 
significant toxicity difference to control at concentrations of 1mM and above 
(n=6, p<0.001, Error bars = Standard Deviation). 
Objective 2: When assessed at equal concentrations in vitro, both 
ketamine (figure 3.5) and nor-ketamine (figure 3.6) were 
cytostatic/cytotoxic to NHU cells. Any difference in toxicity between 
ketamine and nor-ketamine at different doses above 1mM was statistically 
not significant over a 7 day time course (figure 3.7). 
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Figure 3.7 (data extracted from figures 3.5 and 3.6): Comparison of toxicity 
induced in NHU cell cultures by ketamine or nor-ketamine treatment at day 5 
(representative data) showed no statistically significant differences (p>0.05) 
apart from the 0.5mM treatment (p<0.001) (n=6, Error bars = Standard 
Deviation). 
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Figure 3.8: Single ketamine treatment of NHU cells with 0.6 – 1mM ketamine 
showed that it was toxic at concentrations of 1mM and above when compared 
to control from day 4 onwards (n=6, Error bars = Standard Deviation). 
Figure 3.9: Daily ketamine treatment of NHU cells with 0.6 – 1mM ketamine 
showed that toxicity was increased if ketamine was given daily. This was 
evident at concentrations of 0.8mM and above from day 4 onwards (n=6, Error 
bars = Standard Deviation). 
 
Objective 3: The experiment showed that daily treatment of ketamine 
was more toxic to NHU cells at concentrations of 0.8mM and above when 
compared to a single dose at the same concentrations (figures 3.8, 3.9, 
3.10, 3.11, 3.12 and 3.13). In clinical practice this is significant as patients 
abusing/using ketamine daily might be at a higher risk to develop KIC. 
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Figure 3.10 (data extracted from figures 3.8 and 3.9): Comparison of control 
column (no ketamine treatment) of NHU cells from both sets of plates showing 
that the growth of cells is not affected by the change of medium daily (n=6, 
p=0.1401, Error bars = Standard Deviation). 
 
Figure 3.11 (data extracted from figures 3.8 and 3.9): Ketamine did not show 
a difference in toxicity in either daily or single ketamine dose treated NHU cells 
at a concentration of 0.6mM (n=6, p=0.5858, Error bars = Standard Deviation). 
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Figure 3.13 (data extracted from figures 3.8 and 3.9): Increasing ketamine 
concentration in the treatment solution showed that the toxicity difference 
between daily ketamine treatment and single ketamine treatment was apparent 
earlier (as compared to 0.8mM concentration) from day 2 onwards (n=6, 
p=0.0005, Error bars = Standard Deviation). 
Figure 3.12 (data extracted from figures 3.8 and 3.9): Ketamine was more      
toxic to NHU cells at doses of 0.8mM and above when given daily as  
compared to a single dose from day 4 onwards (n=6, p <0.0001,                 
Error bars = Standard Deviation). 
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Figure 3.14: NHU cells treated with MK-801 showed same growth as the cells 
in control column (no treatment)(n=4-6, p=0.1063, Error bars = Standard 
Deviation). 
Objective 4: Using MK-801 as a specific NMDA receptor antagonist, the 
experiment showed that although MK-801 does not cause any toxicity of 
NHU cells on its own, it enhances the toxicity of ketamine when used in 
combination (figures 3.14, 3.15 and 3.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20000
40000
60000
80000
100000
120000
140000
160000
180000
0 1 2 3 4 5 6 7 8 9 10
C
e
ll
 N
u
m
b
e
r 
Day 
Control MK-801
 55 
Figures 3.15 and 3.16: (cells treated with MK-801 only did not show any 
statistically significant difference in growth pattren from the cells with no 
treatment [figure 3.14], number of cells treated with MK-801 alone were 
therefore used as control for figures 3.15 and 3.16); NHU cells treated with a 
combination of ketamine and MK-801 showed more toxicity than ketamine 
alone (n=6, p<0.001, Error bars = Standard Deviation). 
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3.6 Discussion 
The toxicity difference between different concentrations of ketamine might 
explain why patients develop symptoms at different times after ketamine 
abuse/use. This might also be contributed by the individual differences in 
patient’s susceptibility to develop KIC due to internal body’s defence 
mechanisms.  
Ketamine was toxic to NHU cells at concentrations of 0.4mM and above. 
1mM of ketamine solution used for the experiments was equivalent to a 
clinical dose of 0.27419mg/ml/day (0.4mM = 0.11mg/ml/day). Literature 
reports suggested that patients using ketamine for pain relief and as a 
recreational drug developed symptoms of KIC at doses from 200mg/day to 
20g/day respectively [3, 85]. When the experimental and clinical doses 
were converted, they seemed to be comparable (above clinical doses 
approximately equivalent to 0.0024mg/ml/day to 0.248mg/ml/day for a 
patient with body weight of 70kg and assuming that 1g = 1ml). 
As nor-ketamine was equally toxic to NHU cells and stays longer than 
ketamine in the urine [81], it is possible that it may cause more damage to 
the NHU cells. This will be important information for any future therapies 
aimed at blocking the urinary effects of ketamine. 
Although recreational ketamine use is increasing (reviewed by [8, 12]), the 
number of patients presenting with KIC is not. This may be due to under-
reporting of the problem but is more likely due to people using it 
occasionally at parties etc. This gives urothelium time to recover from 
damage before next dose and therefore users experience only temporary 
symptoms after each occasional dose. The above hypothesis was tested 
by the experiments which showed that daily ketamine use was more toxic 
to NHU cells as compared to a single dose. 
Ketamine is primarily used in clinical practice for its NMDA receptor 
antagonist properties and has shown toxicity via this receptor in neuronal 
cell systems in animal models [82, 83]. Although, ketamine has a highly 
promiscuous receptor binding profile, it is possible that same mechanism 
is responsible for causing urothelial toxicity. The experiment showed some 
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interesting results; MK-801, which is a specific NMDA receptor antagonist, 
did not cause urothelial damage on its own but enhanced the toxic effects 
of ketamine when used in combination. This may be due to either 
ketamine inducing expression of NMDA receptor in urothelial cells on 
which MK-801 acts or due to a different receptor pathway responsible for 
urothelial toxicity of ketamine and MK-801 induces increased expression 
of that receptor.  
Although all the above experiments were performed following strict 
protocols, there was some variation in the results in objective 1, 
experiment 2 (figure 3.4) and objective 2 (figure 3.5). Ketamine showed 
statistically significant toxicity at doses of 0.4mM in the first experiment but 
no toxicity at a higher dose of 0.5mM in the second experiment. This might 
be due to donor variability as the cell lines used in the two experiments 
were different. It is unlikely to be due to variations in the prepared 
ketamine concentrations used to treat NHU cells as ketamine is a stable 
drug and the ketamine solutions were prepared fresh each time using the 
same protocols.  
 
3.7 Conclusions 
1. Ketamine is toxic to NHU cells and the toxicity increases as the 
concentration of ketamine is increased.  
2. Toxic effects of ketamine are a result of both itself and its primary 
metabolite (nor-ketamine). 
3. Daily ketamine use is more toxic to NHU cells than a single dose. 
4. In vitro toxic effects of ketamine on NHU cells are enhanced by 
specific NMDA antagonist MK-801 despite no direct toxicity. 
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4 Characterisation of ketamine affected human 
urothelium 
 
4.1 Introduction 
As the awareness increases among the medical community worldwide 
about development of ketamine-induced cystitis (KIC) in abusers and 
prescription users of ketamine, increasing number of literature reports are 
being published about this condition. Most of these reports though 
describe the clinical presentation and management of KIC patients and 
limited reports are about the characterisation of ketamine affected human 
urothelium. Oxley et al. [16] performed immunohistochemistry (IHC) 
experiments to establish the expression of Ki67, p53 and CK20 antibodies 
in 10 KIC samples. In their cohort, 9/10 patients had high p53 
immunoreactivity and 7/10 patients had moderate to high levels of Ki67 
reactivity, but all were negative for CK 20. They concluded that ketamine 
could lead to reactive urothelial changes that could mimic carcinoma in 
situ (CIS).  
Although, this might be useful information in the context of distinguishing 
KIC from bladder CIS, it unfortunately did not help to understand 
aetiopathological mechanisms of disease development in patients with 
KIC and therefore a more detailed IHC study was needed. 
 
4.2 Aim 
To describe human urothelial tissue damage caused by ketamine. 
 
 4.3 Objectives 
Objective 1: To assess proliferation potential in human KIC tissue. 
Objective 2: To assess differentiation potential in human KIC tissue. 
Objective 3: To assess inflammatory changes in human KIC tissue. 
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4.4 Experimental approach 
All antibody staining was performed using protocol 2.2.6 described in the 
materials and methods chapter. Anti-human NGFR antibody staining was 
kindly performed by Dr F Wezel. CD3 antibody staining using H2O2 
prepared in distilled water was unsuccessful, and therefore was performed 
with H2O2 prepared in PBS to increase the staining of antigenic sites 
(http://www.ihcworld.com/_technical_tips/peroxidase_tips.html, website 
accessed 22/06/2011).  
The immunohistochemistry experiments were performed in the following 
order; 
1. H&E staining of normal human urothelial (NHU) tissue was 
performed first to understand the appearance of normal tissue.  
2. H&E staining was performed on 11 KIC tissue blocks from three 
separate patients (KIC1, KIC2 and KIC3) and based on the results 
three individual KIC tissue blocks (KIC1a, KIC2b and KIC3d) 
expected to provide most information during IHC experiments were 
selected (one from each patient).  
3. Based on the information obtained from H&E staining of KIC tissues 
and advice from Dr J Stahlschmidt (Histopathologist at the St 
James’s University Hospital, Leeds), an initial antibody panel was 
agreed with the researchers at the Jack Birch Unit (JBU) of Molecular 
Carcinogenesis, Department of Biology, University of York. 
4. The antibodies were first tested on control tissue to check their 
working condition. Negative sections were included for all antibodies. 
5. The antibody panel was then performed on the three individual KIC 
tissues selected after initial H&E staining. Positive and negative 
control tissues were included for each antibody. Positive labelling 
index was determined for some antibodies by selecting urothelial or 
stromal areas at five random sites in the section and calculating the 
percentage by counting the positive cells against the total number of 
cells using a x60-oil objective. 
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6. Table 1 below shows the selected antibody panel; 
 
Antibody Host Localise  Antigen Retrieval 
Method 
Dilution 
(optimised) 
Ki67 Mouse Cells in cell cycle Microwave (citric acid) 1:100 
UPK3a Mouse Differentiation and 
Superficial cells 
Microwave (citric acid) 1:40 
CK20.8 Mouse Superficial cells Trypsin 1:200 
CK13 Mouse Basal and 
Intermediate cells 
Trypsin & Microwave 1:100 
CK5 Rabbit Basal cells Microwave (citric acid) 1:100 
CK14 Mouse Squamous 
Metaplasia 
Trypsin & Microwave 1:100 
CD34 Mouse Number and size 
of blood vessels 
Trypsin 1:50 
CD3 Mouse T-cells Microwave (citric acid) 1:25 
CD68 Mouse Macrophages and 
Monocytes 
Microwave (citric acid) 1:50 
Mast Cell 
Tryptase 
Mouse Mast cells Microwave (citric acid) 1:300 
CD117 Rabbit cKit positive cells Microwave (citric acid) 1:600 
Anti-
human 
NGFR 
Mouse Neural fibrosis and 
inflammation 
Microwave (citric acid) 1:100 
 
 
 
 
 
 
 
Table 4.1: Initial antibody panel for the three inidividual KIC tissue sections 
based on the H&E staining results. 
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Figure 4.2: H&E staining of 11 KIC tissue blocks from three individual patients 
was performed first. Three most informative blocks for future Immunolabelling 
experiments were selected. H&E staining of these blocks demonstrated tissue 
damage in the form of epithelial denudation and inflammation of the tissue 
evident by oedematous blood vessels in the lamina propria. Scale bar 100µm. 
Figure 4.1: H&E 
staining of a section of 
normal human ureter 
demonstrating a 
transitional epithelium 
with three layers 
(Superficial, 
Intermediate and basal) 
and underlying 
submucosa, scale bar 
100µm. 
4.5 Results 
4.5.1 Normal Urothelium 
 
 
 
 
 
 
 
 
 
 
4.5.2 H&E staining of KIC tissue 
H&E staining of the three individual KIC tissues selected to perform the 
initial antibody panel showed denudation of epithelium in two individual 
sections (KIC1a and KIC3d) and oedematous vessels in the lamina 
propria of two individual sections (KIC2b and KIC3d). A rich cellular 
infiltrate likely to be immune in nature was also present in the lamina 
propria of all three individual KIC tissue sections. 
 
 
 
 
 
 
 
             (KIC1a)                                (KIC2b)                               (KIC3d) 
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Figure 4.3: Colonic 
metaplasia on H&E 
staining in one (KIC3b) 
out of four tissue blocks 
from one individual 
patient (KIC3), scale bar 
100µm. 
Figure 4.4: Section of 
human ureter with 
occasional Ki67 
positive proliferating 
cells in urothelium, 
scale bar 5µm. 
In addition, H&E staining of tissue sections from one of the blocks (KIC3b) 
from patient KIC3 demonstrated intestinal (columnar) metaplasia (scale 
bar 100µm). 
 
 
 
 
 
 
 
 
 
 
 
4.5.3 Antibody panel for KIC tissues 
The antibody panel was checked on control (normal) tissue to confirm its 
working condition. Negative controls were included for all antibodies. 
 
Proliferation marker: 
Ki67 
 
 
 
 
 
 
 
 
 
 
 
(KIC3b) 
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Figure 4.5: Section of 
human ureter with 
UPK3a positive cells in 
superficial layer of 
urothelium, scale bar 
5µm. 
Figure 4.6: Section of 
human ureter with 
CK20.8 positive cells in 
superficial layer of 
urothelium, scale bar 
5µm. 
Figure 4.7: Section of 
human ureter with 
CK13 positive cells in 
basal and intermediate 
layers of urothelium, 
scale bar 5µm. 
Differentiation markers: 
UPK3a 
 
 
 
 
 
 
 
 
 
CK20.8 
 
 
 
 
 
 
 
 
CK13 
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Figure 4.8: Section of 
human ureter with CK5 
positive cells in basal 
layer of urothelium, 
scale bar 50µm. 
Figure 4.9: Section of 
human skin with CK14 
positive Squamous 
epithelium, scale bar 
50µm. 
Figure 4.10: Section  
of human colon with 
mucus producing 
Alcian blue positive 
glands, scale bar 
50µm. 
CK5 
 
                                                                       
 
 
 
 
 
 
 
 
Metaplasia Markers: 
CK14 
 
 
 
 
 
 
 
 
 
AB-PAS with diastase digestion  
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Figure 4.11: Section  
of human colon with   
CD3 positive T-cells in 
a lymph node in the 
submucosa, scale bar 
50µm. 
Figure 4.12: Section  
of human ureter with 
CD34 positive blood 
vessels in submucosa 
and positive stromal 
fibres, scale bar 
100µm. 
Figure 4.13: Section  
of human lymph node 
with CD68 positive 
macrophages and 
monocytes, scale bar 
100µm. 
Inflammation markers: 
CD3 
 
 
 
 
 
 
 
 
 
CD34 
 
 
 
 
 
 
 
 
 
CD68 
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Figure 4.14: Section 
of human ureter with 
Mast Cell Tryptase 
positive mast cells in 
the submucosa, scale 
bar 100µm. 
Figure 4.15: Section 
of human ureter with 
CD117 positive cells in 
the urothelium and 
positive mast cells in 
the submucosa, scale 
bar 100µm. 
Figure 4.16: Section 
of human ureter with 
Anti-human NGFR 
positive cells in the 
basal layer of 
urothelium, scale bar 
50µm. 
Mast Cell Tryptase 
 
 
 
 
 
 
 
 
 
CD117 
 
 
 
 
 
 
 
 
 
Anti-Human NGFR 
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Figure 4.17: One of 
the human ureter 
sections used as a 
negative control for 
antibodies Ki67, 
UPK3a, Mast Cell 
Tryptase, CK13, Anti-
human NGFR, CK20.8, 
CD34, CD68, CD117 
and CK5, scale bar 50 
µm. 
Figure 4.19: Negative 
control section of 
human skin for CK14, 
scale bar 50µm. 
Figure 4.18: Negative 
control section of 
human ureter for     
AB-PAS with diastase 
digestion staining, 
scale bar 50µm. 
4.5.3.1 Negative control sections for antibody panel 
 
Human ureter 
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Human skin 
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Figure 4.20: Negative 
control section of 
human colon for CD3 
antibody, scale bar 
50µm. 
Human colon 
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   (KIC1a)                              (KIC2b)      (KIC3d) 
Figure 4.21: Immunoperoxidase labelling of the three individual KIC tissue 
sections with Ki67 showed increased proliferation in the urothelium of two 
sections (KIC1a and KIC3d) and negative in one section (KIC2b). A section of 
normal human ureter (E) was included as a positive control and one as a 
negative control (F). Scale bar 50µm. 
4.5.4 Immunoperoxidase staining of KIC tissue sections with 
antibodies from the panel 
4.5.4.1 Ki67 
Ki67 was used as a marker of proliferation in the urothelium. The 
immunolabelling showed that proliferation (and therefore tissue turnover) 
was increased in two (KIC1a and KIC3d) of the three individual KIC 
sections (increased Ki67 expression in urothelium). Although section 
KIC1a had largely denuded urothelium reduced to a simple epithelial layer, 
the remaining urothelial cells showed increased proliferation (positive 
labelling index 7/23, 30.43% as compared to 12/85, 14.12% in positive 
control section). Positive labelling index of Ki67 positive cells in the 
urothelium of section KIC3d was 31/110, 28.18% as compared to 12/85, 
14.12% in positive control tissue.     
 
 
  
 
 
 
 
 
 
 
                           
 
 
                           
 
 
 
 
 
(E)     (F) 
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Figure 4.22: Immunoperoxidase labelling of the three individual KIC tissue 
sections with UPK3a showed presence of the protein in one (KIC2b) and 
absence in two sections (KIC1a and KIC3d). A section of normal human ureter 
(E) was included as a positive control and one as a negative control (F). Scale 
bar 50µm. 
        (KIC1a)                                (KIC2b)   (KIC3d) 
4.5.4.2 UPK3a 
The apical surface of the superficial cell membrane of urothelium is 
covered with multiple thickened plaques of asymmetric unit membrane, 
known collectively as uroplakins [53]. These integral transmembrane 
proteins are responsible for maintaining transcellular permeability [53]. 
UPK3a was selected for the experiments to assess presence of uroplakin 
along the superficial edge of the urothelium and therefore differentiation.  
The labelling showed that UPK3a was positive only in one of the 3 
individual KIC sections (KIC2b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)     (F) 
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Figure 4.23: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CK20.8 showed positive labelling in one (KIC2b) and negative 
labelling in two sections (KIC1a and KIC3d). This signifies loss of superficial  
cells in the urothelium in sections KIC1a and KIC3d. A section of normal human 
ureter (E) was included as a positive control and one as a negative control (F). 
Scale bar 50µm. 
      (KIC1a)                                (KIC2b)           (KIC3d) 
4.5.4.3 CK20.8 
Cytokeratins (CK) are a group of proteins found only in the epithelial cells, 
with different CK types expressed differentially by different epithelial types 
and differentiation stages. CK20.8 was selected for the experiments to 
assess presence of superficial layer of urothelium. 
The labelling showed positive expression in one section (KIC2b) but 
negative in the other two sections (KIC 1a and KIC3d). This further 
enforces the results of UPK3a antibody which showed absence of 
superficial cells in urothelium in sections KIC1a and KIC3d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
(E)     (F) 
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Figure 4.24: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CK13 showed positive labelling in all three sections. This 
demonstrated that although superficial cells were absent in sections KIC1a and 
KIC3d (UPK3a and CK20.8 negative), they still had cells of an intermediate 
and/or basal urothelial phenotype. A section of normal human ureter (E) was 
 included as a positive control and one as a negative control (F). Scale bar 
50µm. 
       (KIC1a)                               (KIC2b)                      (KIC3d) 
4.5.4.4 CK13 
As the superficial layer of urothelial cells was absent in two (KIC1a and 
KIC3d) of the three individual sections, the next step was to identify 
whether the remaining cells were from intermediate and basal layers, and 
CK13 was selected for this purpose. 
CK13 was expressed by all three individual KIC sections demonstrating 
that all had intermediate and basal urothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
(E)     (F) 
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Figure 4.25: Immunoperoxidase labelling of the three individual KIC tissue    
 sections with CK5 showed positive labelling in all three sections. CK13 
(previous page) and CK5 positive cells in urothelium in all three sections 
demonstrated that the cells were from both basal and intermediate layers. A 
section of normal human ureter (E) was included as a positive control and one 
as a negative control (F). Scale bar 50µm. 
         (KIC1a)                               (KIC2b)              (KIC3d) 
4.5.4.5 CK5 
Although CK13 confirmed presence of intermediate and basal layer of 
cells in urothelium, it could not distinguish between the two types of cells 
and CK5 was therefore selected which is preferentially expressed by cells 
in the basal layer of urothelium only. 
The labelling showed that the urothelial cells in section KIC1a were mainly 
basal in nature while those in KIC2b and KIC3d were both basal and 
intermediate in nature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
 
 
(E)     (F) 
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      (KIC1a)                                (KIC2b)          (KIC3d) 
Figure 4.26: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CK14 showed absence of labelling in all three sections. A section 
of normal human skin (E) was included as a positive control and one as a 
negative control (F). Scale bar 50µm. 
4.5.4.6 CK14 
When exposed to stress, the urothelium can sometimes undergo 
metaplastic changes which is a process of change of epithelium from one 
form to another to withstand the changing environment pressures. Chronic 
infections of urothelium can lead to metaplasia of the urothelial cells from 
normal transitional epithelium to squamous epithelium.  
CK14 was therefore selected to examine the possibility of change of 
urothelium in KIC patients to squamous type under the stress from 
ketamine.  
The experiment showed absence of CK14 expression in all 3 individual 
KIC sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)     (F) 
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         (KIC1a)                              (KIC2b)              (KIC3d) 
Figure 4.27: Alcian blue staining of the three individual KIC tissue sections 
showed no increased in mucus in any of the sections. A section of normal 
human colon (E) was included as a positive control and a section of normal 
human ureter (F) was included to show the appearance of normal urothelium 
after AB-PAS with diastase digestion staining. Scale bar 50µm. 
4.5.4.7 AB-PAS with diastase digestion  
Surface of urothelium is protected by a glycocalyx or GAG layer. In certain 
chronic bladder uropathies such as painful bladder syndrome/IC, it is 
hypothesised that damage to this layer leads to development of symptoms 
[24]. Not only the tissue under stress can have metaplasia but also 
hyperplasia (increased number of normally found cells) of the tissue. It is 
therefore possible that chronic exposure to ketamine in patients with KIC 
may lead to an increase in the number of mucus producing glands as a 
protective mechanism and Alcian blue was selected to indicate any 
mucus. 
The experiment showed that there was no increase in mucus producing 
glands in any of the three individual KIC tissue sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)     (F) 
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(KIC1a)                            (KIC2b)    (KIC3d) 
Figure 4.28: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CD34 showed increased number of oedematous blood vessels in 
sections KIC1a and KIC3d. A section of normal human ureter (E) was included 
as a positive control and to demonstrate the normal distribution of blood  
vessels, and a section of normal human ureter (F) was included as a negative 
control. Scale bar 50µm. 
4.5.4.8 CD34 
H&E staining of the three individual KIC tissue sections showed 
oedematous vessels. CD34 was selected as the antibody to evaluate the 
presence of blood vessels. 
The antibody labelling demonstrated oedematous blood vessels in 
sections KIC1a and KIC3d, and normal blood vessels pattern in section 
KIC2b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)       (F) 
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(KIC1a)                                 (KIC2b)       (KIC3d) 
Figure 4.29: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CD3 showed T-cell rich stromal infiltrate in sections KIC2b and 
KIC3d, and increased number of T-cells in the urothelium in section KIC3d. A 
section of normal human colon (E) was included as a positive control and one 
(F) as a negative control. A positive section of normal human ureter (G) was  
also included to demonstrate the number of T-cells in a normal urothelial    
tissue. Scale bar 100µm. 
4.5.4.9 CD3 
To evaluate the rich cellular infiltrate in the lamina propria, CD3 was used 
as the antigen to assess whether these cells were T-cells. 
The labelling showed absence of CD3 staining in one (section KIC1a) and 
CD3 positive T-cells infiltrate in the other two sections (KIC2b and KIC3d). 
In addition, the number of T-cells in urothelium in section KIC3d was also 
increased (positive labelling index 53/120, 44.17% as compared to 12/113, 
10.62% in the urothelium of control tissue). 
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          (KIC1a)                              (KIC2b)                       (KIC3d) 
Figure 4.30: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CD68 showed few positive cells in the stroma of all sections and 
some positive cells in the urothelium of sections KIC2b and KIC3d. A section of 
normal human liver (E) was included as a positive control and a section of 
normal human ureter (F) as a negative control. Scale bar 50µm. 
4.5.4.10 CD68 
The next step was to assess whether any of the other inflammatory cells 
were infiltrating the KIC tissue. For assessing the presence of 
macrophages (and monocytes), CD68 was used as the antibody marker.  
The experiment showed that all sections had a few positive cells mainly 
associated with blood vessels in the stroma. In addition, sections KIC2b 
and KIC3d also had some CD68 positive cells in the urothelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)     (F) 
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         (KIC1a)                               (KIC2b)             (KIC3d) 
Figure 4.31: Immunoperoxidase labelling of the three individual KIC tissue 
sections with mast cell tryptase showed no increase in the number of mast cells 
in the stroma of either of them. A section of normal human ureter (E) was 
included as a positive control and one (F) as a negative control. Scale bar  
50µm. 
4.5.4.11 Mast Cell Tryptase 
Ketamine might be causing an allergic reaction to urothelium and mast 
cells play an important role in this aspect. To assess the number of mast 
cells in the three individual KIC tissues, mast cell tryptase was selected as 
the antibody marker. 
The labelling showed that although mast cells were present in all three 
individual KIC tissue sections, they were not increased in number. Positive 
labelling index; section KIC1a 9/57, 15.79%, section KIC2b 5/42, 11.9% 
and section KIC3d 9/54, 16.67% as compared to the positive labelling 
index of mast cells in the stroma of positive control; 11/50, 22%. 
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         (KIC1a)                               (KIC2b)            (KIC3d) 
Figure 4.32: Immunoperoxidase labelling of the three individual KIC tissue 
sections with CD117 showed no increase in expression of the antigen in any of 
them. A section of normal human ureter (E) was included as a positive control 
and one (F) as a negative control. Scale bar 50µm. 
4.5.4.12 CD117 
The proto-oncogene CD117 (c-kit) is a non-specific transmembrane 
receptor for SCF (stem cell factor) and is often associated with stem/ 
progenitor cells in various organs such as prostate, cardiac, bone marrow 
or hematopoietic stem cells [80]. It can also be found in more differentiated 
cell types such as mast cells [86].  
The potential role of these cells in vivo might range from a less 
differentiated progenitor cell type to a more differentiated cell with specific 
functions, such as mechano-sensation or neuroendocrine function [80]. 
Immunoperoxidase labelling using CD117 was therefore performed to 
assess whether there was increase in the expression of these cells in the 
KIC tissue. The labelling showed CD117 positive mast cells in the stroma 
of all three individual KIC tissue sections and no positive cells in the 
urothelium of any of the sections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)      (F) 
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          (KIC1a)                               (KIC2b)     (KIC3d) 
Figure 4.33: Immunoperoxidase labelling of the three individual KIC tissue 
sections with anti-human NGFR showed positive cells in the basal layer of 
sections KIC2b and KIC3d, and increased expression of the antibody in the 
submucosa of all three individual KIC tissue sections. A section of normal  
human ureter (E) was included as a positive control and one (F) as a negative 
control. Scale bar 50µm. 
4.5.4.13 Anti-human NGFR 
NGFR is a cell membrane receptor protein whose expression has been 
demonstrated in urothelium from human neuropathic bladder patients [87] 
and also in animal models where urothelium was damaged e.g. by 
cyclophosphamide instillation [88, 89]. It is also expressed by the basal 
layer of urothelium in the upper urinary tract (renal pelvis and ureter) [80]. 
In a normal human ureter section (E), anti-human NGFR was only 
expressed by the basal layer of urothelial cells. In the KIC tissues though, 
in addition to the positive basal urothelial cells in sections KIC2b and 
KIC3d, major expression was also found in the stromal cells of all three 
individual KIC sections. These cells in the stroma could be either myocytes 
or neurites and further antibody labelling will be needed to establish their 
exact nature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)     (F) 
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4.6 Discussion 
The human urinary tract is covered from the renal pelvis to the proximal 
urethra by transitional epithelium (urothelium). It consists of three layers of 
cells i.e. basal, intermediate and superficial. Transitional epithelium is a 
highly specialised structure in that it not only forms a tight barrier 
preventing urine and toxic agents passing in to the underlying tissues but 
also can contract and expand in response to the volume of urine in the 
bladder. Urothelium is mitotically quiescent in normal circumstances but 
becomes highly proliferative in response to injury. 
Ketamine causes damage to the human urinary tract and can lead to the 
development of a florid non-bacterial cystitis condition known as ketamine-
induced cystitis (KIC). This study was aimed at identifying changes caused 
by ketamine in human urothelium so that it might help us understand 
possible mechanisms of development of KIC. 
In this multicentre study, several difficulties were experienced in collecting 
a reasonable number of KIC tissues to perform the immunohistochemistry 
experiments. The main problem encountered was obtaining Research and 
Development (R&D) approval at multiple sites to transport tissue to the 
University of York for experiments. Although, R&D approval was gained at 
two sites and 20 individual KIC tissue blocks were eventually available, 
some of the tissues were significantly small in size. This meant that not all 
antibodies from the panel could be performed on each of the blocks 
without some useful initial information first. As there are no detailed 
immunohistological studies on KIC published in literature so far, no 
previous guidance was available from that aspect. It was therefore 
decided (between the scientists at the Jack Birch Unit of Molecular 
Carcinogenesis, University of York and a Histopathologist at the St 
James’s University Hospital, Leeds) to select an initial antibody panel 
based on H&E results from the three individual KIC tissue sections 
selected. The agreed antibody panel was performed on these three 
individual KIC tissue sections and showed some interesting results; 
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1. H&E staining showed inflamed and apparently dysplastic tissue with 
loss of cohesion in epithelium. Clinical history in these patients is of 
utmost importance as without that it would be very easy to diagnose a 
carcinoma in situ (CIS) on the basis of histology alone. 
2. Absence of superficial cells in the two (KIC1a and KIC3d) individual 
KIC tissue sections was associated with increased proliferation in the 
remaining urothelial cells. An interesting point here is that 
proliferation was absent in section KIC2b which had superficial cells 
and therefore intact barrier function. Urothelial damage by ketamine 
may therefore induce proliferation in cells in the basal and 
intermediate layers to try and re-store the barrier function of 
urothelium. 
3. Human urothelium is known to undergo metaplasia in response to 
chronic infection or inflammation and transforms from a normal 
transitional to a metaplastic squamous epithelium to withstand the 
rigours of the environment. However, there was no evidence of 
urothelial metaplasia in any of the three individual KIC tissue 
sections, as one might expect in response to the chronic 
inflammation caused by ketamine. 
4. Inflammation as evidenced by oedematous blood vessels was 
present in two (KIC1a and KIC3d) of the three individual KIC tissue 
sections. Sections KIC1a and KIC3d also had absent superficial layer 
of urothelium and therefore the barrier function was lost leaving 
stroma exposed to the harmful effects of toxic urine components 
including ketamine and its metabolites. This may represent one of the 
mechanisms by which ketamine induces inflammation in the 
urothelial tissue and the resultant development of KIC symptoms. 
5. The rich cellular infiltrate in the stroma of two (KIC2b and KIC3d) of 
the three individual KIC tissue sections and in the urothelium in one 
of the individual sections (KIC3d) was mainly T-cells. Amongst other 
inflammatory adaptive responses of a tissue, T-cells are also 
associated with type IV delayed hypersensitivity reaction and this may 
represent another mechanism by which ketamine abuse/use leads to 
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the development of KIC. This is further supported by the clinical 
evidence that patients presenting with KIC symptoms have usually 
abused/used ketamine for a while before permanent urinary tract 
damage happens.  
This was an interesting finding as ketamine managed to induce 
inflammatory changes (increased number of T-cells in the stroma) in 
the one individual KIC tissue section (KIC2b) with superficial cells 
and intact barrier function. This might mean that action of ketamine on 
urothelium is two fold: direct toxic effect on the superficial cells and a 
receptor mediated effect to cause damage in the deeper tissue. 
There was further evidence of inflammation as indicated by the 
increased anti-human NGFR labelling in the submucosa of all three 
individual KIC tissue sections and might signify possible neural 
fibrosis and inflammation. The positive cells in the stroma could be 
either neurites or myocytes and further antibody labelling would be 
needed to establish their exact nature. 
Some of the other cells (macrophages, monocytes and mast cells) 
which are well known to take part in inflammatory and allergic 
reactions did not seem to participate towards the development of 
KIC. There was also no evidence of a mechano-sensitive cell 
population in the urothelium which if present might have become 
active in response to the urothelial injury caused by ketamine.   
 
4.7 Conclusions 
The results obtained from this pilot study have helped to understand the 
urothelial tissue damage caused by ketamine and indicated the possible 
pathways which might lead to the development of KIC although 
establishing a definite aetiopathological mechanism of development of KIC 
at this stage is not possible. This is the first detailed immunohistological 
study of the human KIC tissue and based on these results, future 
experiments will be performed aimed at expanding on the information 
gained already. 
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5 Relationship between dose, duration and 
frequency of ketamine use and development of 
ketamine-induced cystitis (KIC) 
 
5.1 Introduction 
Ketamine is a phencyclidine derivative NMDA receptor antagonist used in 
clinical practice for anaesthesia (reviewed by [90]), analgesia ([3-5] and 
reviewed by [6]) and is under research to develop next generation of fast 
acting anti-depressants (reviewed by [7]).  
Ketamine has been a target of recreational drug users for many decades 
[10] and although literature reports ([91] and reviewed by [12]) and 
anecdotal experience suggests that ketamine abuse is on the rise, the 
number of patients presenting to Urology clinics is not. This may be due to 
one of the following reasons; 
1) The pattern of use; occasional (weekend/parties) use which allows 
bladder time to recover and it is only with sustained use that 
irreversible scarring and damage is likely to occur. 
2) Non-association by drug abusers of the problem of non-bacterial 
cystitis with ketamine abuse. 
3) Under reporting of the problem as ketamine is an illegal drug. 
KIC has also been reported in patients using analgesic ketamine for 
weeks to months and the symptoms either improved or completely 
resolved in all patients following stopping or reducing the dose [3, 14]. 
However, we have recently reported a case of a patient who used 
analgesic ketamine for longer (three years) than the above reports and 
developed bladder symptoms which persisted even after stopping the drug 
and resulted in surgical treatment [92]. Also, the in vitro experiments 
showed that ketamine toxicity to normal human urothelial (NHU) cells 
increased as the concentration of the drug was increased and also by 
treating them daily with ketamine. It is therefore possible that development 
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of KIC is related to the dose, duration or frequency of ketamine used and 
the aim of this study was to test this hypothesis. 
 
5.2 Materials and Methods 
Recreational drug users can be a difficult patient group to manage in the 
clinic due to their un-cooperative behaviour and unwillingness to attend for 
clinical appointments, the same is the case with ketamine abusers. 
Furthermore, it is often quite difficult to establish the accurate exposure of 
drug of abuse from recreational drug users. Ketamine is increasingly used 
as a third line analgesic for chronic pain treatment [14] and this cohort of 
patients was identified as a useful group to investigate the above 
hypothesis. 
The study was carried out at the James Cook University Hospital (JCUH), 
Middlesbrough and was approved as an amendment to the original 
research project by the ethics and, the research and development (R&D) 
committees. 
All patients dispensed ketamine for pain relief from the pharmacy 
department at the James Cook University Hospital (JCUH), Middlesbrough 
between April 2007 and March 2011 were included in this study. These 
patients were assessed using a telephone questionnaire (figure 5.1) and 
managed using the management flow chart (figure 5.2) approved by the 
ethics and R&D committees. 
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Figure 5.1: The telephone questionnaire used to investigate patients 
using analgesic ketamine for any urinary tract symptoms. 
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Figure 5.2: The management flow chart for any patients found to have 
urinary symptoms following the KIC questionnaire. 
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5.3 Results  
A total of 61 patients were identified who were dispensed ketamine from 
pharmacy department at the JCUH, Middlesbrough between April 2007 
and March 2011. More than one month (arbitrary value) duration of use of 
ketamine was considered as significant and any patients who used it for 
less than four weeks were excluded. In total, 32 of the 61 patients had to 
be excluded due to various reasons (figure 5.3).  
 
 
 
 
 
 
 
0 2 4 6 8 10 12
Unable to contact (11)
Died (8)
Used for 4 weeks or less (8)
Could not remember taking it (2)
Had dispensed but did not use it (1)
Catheterised and had no bladder
sensation (1)
Had cystectomy before started
using ketamine (1)
Figure 5.3: 32 patients excluded from the study and the reasons for    
their exclusion. 
Number of patients  
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A total of 29 patients were included in the study who were either currently 
taking ketamine, or had taken it in the past for four weeks or more and had 
now stopped taking it due to either the side effects or no pain relief. 17 
patients were males and 12 females, age ranged from 41 – 79 years with 
a mean age of 57.7 years. All patients were using ketamine in the liquid 
form and 1ml of the dispensed solution contained 10mg. 
Six of the 29 patients were found to have urinary symptoms significant 
enough to offer further investigations. Four of these six patients were 
females and two males, age ranged from 42 – 67 years with mean age of 
56.1 years. The duration of use ranged from ten months – eight years and 
the dose from 40mg/day – 375mg/day (table 5.1). One or more of the 
following urinary tract symptoms were reported by these six patients after 
analgesic ketamine use; daytime frequency, nocturia, abdominal pain and 
urinary incontinence (figure 5.4). 
 
Age Sex Duration of use Dose Further 
investigations 
53 F 5 years 7.5ml  5 times a day Yes 
55 F 5 years 2.5ml  6 times a day Yes 
67 F 8 years 2.5 – 5ml  QDS/PRN Yes 
42 F 1 year 1-2ml  QDS No (patient choice) 
58 M 10 months – 1 year 5ml  QDS Yes 
62 M 2 years 10ml  BD – TDS  Yes 
 
 
 
 
 
 
 
 
 
Table 5.1: Demographics, dose, duration and frequency of ketamine use in   
the patients found to have significant urinary tract symptoms possibly from 
analgesic ketamine use. 
 
 91 
 
 
 
 
 
 
 
 
 
Of the six patients with symptoms, one had recently stopped taking 
ketamine and did not want any further investigations at present to see if 
stopping the drug will improve their symptoms. Five patients agreed to 
further investigations of their urinary symptoms. Three of these five 
patients have already been seen in the clinic and appropriate 
investigations arranged. The rest will be seen in clinic in the near future for 
further management. 
23 of the 29 patients had no urinary symptoms. 15 of them were males 
and 8 females, age ranged from 41 – 79 years with mean age of 58.1 
years. The duration of use ranged from two months – six years and the 
0 1 2 3 4 5 6 7
Nocturia (6)
Daytime frequency
(5)
Incontinence (2)
Abdominal pain (2)
Number of patients  
Figure 5.4: Frequency of different urinary tract symptoms in the six 
patients with possible urinary tract damage from analgesic ketamine use. 
Note that the symptoms most frequently happening are daytime  
frequency and nocturia which may be due to bladder overactivity in 
response to the damage induced by ketamine. 
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dose from 25mg/day – 600mg/day. Five of the patients who had used 
analgesic ketamine in the past but had now stopped taking it, could not 
remember the dose (table 5.2).  
 
Age Sex Duration of use Dose 
45 F 3-4 years 5ml  QDS 
66 F 5-6 months 2ml  QDS 
48 F 3-4 months 2ml  QDS 
68 F 2 years 2.5ml  BD – TDS PRN 
77 F 4 months 2.5ml  TDS 
79 F 2 years 2.5ml  6 times a day 
58 F 4 years 2.5ml  QDS 
48 F 2 years Could not remember 
59 M 4 years 10ml  6 times a day 
51 M 1 year 5ml  TDS 
60 M 2 months 5ml  TDS 
64 M 6 months 15ml  TDS PRN 
65 M 4 years 5ml  OD 
47 M 2 years 2.5ml  QDS 
47  M 6 years 5ml  QDS 
41 M 1 year 2.5ml  6 times a day 
61 M 6 years 5ml  QDS – 6 times a day 
51 M 1 year 2.5ml OD 
69 M 2 1/2 years 5ml  QDS 
66 M 2 months  Could not remember 
41 M 2 months Could not remember 
58 M 3-4 months Could not remember 
68 M 6 months Could not remember 
 
 
 
Table 5.2: Demographics, dose, duration and frequency of ketamine use in 
the patients with no urinary tract symptoms after analgesic ketamine use. 
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5.4 Discussion 
Ketamine abuse can lead to the development of florid non-bacterial cystitis 
symptoms which can be so severe that some patients have required 
surgical treatment in the form of cystectomy and neobladder formation or 
urinary diversion ([2, 93] and reviewed by [8, 12]). Although the 
anaesthetic dose of ketamine is 0.5 – 2mg/kg, continued use leads to the 
development of tolerance and recreational users have reported abusing 
high doses (up to 20 g/day) (reviewed by [8]). Interestingly, in the 
previously reported cases, prescription users of analgesic ketamine 
developed urinary tract symptoms at much lower doses, from 200mg/day 
to 1g/day [3, 14, 92].  
There is no definite evidence in literature to suggest when the symptoms 
start from ketamine abuse but may be years (anecdotal reports). On the 
other hand, analgesic ketamine use appears to have led to the 
development of KIC after use for weeks to months [3, 14]. Furthermore, 
the in vitro experiments suggest that ketamine is toxic to NHU cells at all 
concentrations and the toxicity increases following daily use as compared 
to a single use (results, chapter 3). 
This raises three interesting questions; 
1. Is development of KIC dependent on the dose of ketamine used? 
2. Is development of KIC dependent on the duration of ketamine used? 
3. Is development of KIC dependent on the frequency of ketamine 
used? 
Due to the small number of ketamine abusers who have presented to us 
so far and the relative difficulty to establish the accurate exposure of 
ketamine from this cohort, patients using analgesic ketamine were 
identified to conduct this study. 
The results showed that a relatively small number of patients (6/29, 
20.7%) using analgesic ketamine experienced either development of or 
deterioration in their lower urinary tract symptoms. There was no clear 
association between the dose, duration or frequency of analgesic 
ketamine used to the development of KIC.  
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Patients using much higher doses (up to 600mg/day) did not report any 
urinary tract symptoms when compared to patients with symptoms of KIC 
(up to 375mg/day).  
Although three of the patients who developed urinary symptoms following 
analgesic ketamine use had used it for 5 years or more, the rest of them 
had used it for ten months to two years and still developed the symptoms. 
Patients who did not report any significant urinary symptoms had also 
used it for a considerable duration (up to six years). 
Patients in both groups (with and without urinary symptoms) reported 
comparable frequency of ketamine use and there was no clear association 
to the development of KIC. 
 
5.5 Conclusions 
This study had some limitations;  
1. There was no age matched control group of patients with same 
medical illnesses and using same medications as patients taking 
ketamine. 
2. No investigations have been done so far to confirm the presence of 
KIC in the six patients who reported urinary symptoms after using 
ketamine for pain relief.    
Within limitations of the study, it is possible that there may be a group of 
patients who are vulnerable to urinary tract damage from ketamine even at 
low prescription doses. However, before drawing any definite conclusions, 
patients reporting lower urinary tract symptoms after analgesic ketamine 
use will be seen in the clinic and investigated appropriately. 
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6 Discussion/Conclusions and future direction of 
research 
Other than being used as an anaesthetic for over 40 years [1, 2], ketamine 
is also increasingly used as an analgesic in chronic pain patients [4-6] and 
three literature reports so far have described the development of urinary 
tract damage in patients using ketamine for analgesia [3, 14, 92].  
Ketamine is also under investigation to develop the next generation of 
rapid acting anti-depressants (reviewed by [7]). Time is of essence in 
patients with depression as they are most vulnerable to self-harm in the 
initial stages. The current conventional anti-depressant therapies take at 
least 4-6 weeks to exert their effects and some of these patients may not 
have that much time. Research in patients with depression treated with 
ketamine has shown improvement in their symptoms in hours to days [94-
96]. This makes ketamine sound like an ideal anti-depressant but the 
problem will be the urinary tract symptoms these patients may develop 
from long term prescription ketamine use and that may in turn lead to the 
re-development of depression symptoms. As no long term trials have been 
done so far on patients using ketamine for treatment of depression, there 
are no literature reports of urinary tract damage either. 
With ketamine gaining popularity among clinicians to treat patients with 
chronic pain and depression, and among recreational drug users as the 
drug of choice to abuse, inevitably more and more patients are going to 
present to the Urology departments with KIC. It is therefore of utmost 
importance to understand KIC as a condition so that effective treatment 
strategies can be developed for these patients. This research project is the 
first step in that direction. 
  
6.1 Possible mechanisms of development of ketamine-
induced cystitis 
Although the Urology community worldwide is becoming increasingly 
aware of ketamine-induced cystitis (KIC) as a condition and there are 
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more than 20 literature reports on the condition so far, the mechanism of 
development of KIC is unknown. Chu et. al. [2] suggested different 
theories but none is proven experimentally.  
The first aim of this research project therefore was to provide some 
experimental evidence about the possible mechanisms of development of 
KIC. A two pronged experimental approach was undertaken for this 
purpose and included cell biology experiments (exposure of normal human 
urothelial cells to different drugs) and immunohistochemistry experiments 
(immunolabelling of the KIC tissue with different antibodies). Although 
these are initial experiments but based on the preliminary results from the 
above experiments, the contributory factors and the possible mechanisms 
of development of KIC in the ketamine users and abusers might be as 
below. 
 
6.1.1 Cell Biology experiments 
In vitro cell biology experiments demonstrated that ketamine was toxic to 
normal human urothelial (NHU) cells and daily treatment was more 
damaging as compared to a single exposure. 
Nor-ketamine (a primary metabolite of ketamine) demonstrated equal 
toxicity to ketamine of NHU cells. The mechanism of action of ketamine on 
NHU cells may therefore be a combination of itself and its primary 
metabolite nor-ketamine.  
Ketamine has a highly promiscuous receptor binding profile (reviewed by 
[9]) and it is possible that one of these receptors is responsible for the 
action of ketamine on NHU cells and therefore development of KIC. In this 
respect, NMDA receptor seemed to be the obvious target for urothelial 
ketamine effects based on the reports of neuronal toxicity via the same 
receptor pathway in animal models [82, 83], but the work presented here 
did not support this. 
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6.1.2 Immunohistochemistry experiments 
The absence of superficial layer of urothelium in two of the three individual 
KIC tissue sections used for immunohistochemistry experiments signified 
that the barrier function was lost. This was further evidenced by increased 
proliferation rate in the remaining urothelial cells in the same two individual 
KIC tissue sections and might represent an attempt by the tissue to re-
generate superficial cells to try and re-store the barrier function.  
Loss of barrier function left the remaining cells vulnerable to toxic urinary 
components particularly ketamine and its primary metabolite nor-ketamine, 
and therefore development of inflammation. This was evidenced by 
oedematous blood vessels, increased T-cells and anti-human NGFR 
antibody expression in the KIC tissues. Inflammation in bladder tissue 
could then lead to the development of lower urinary tract symptoms 
(LUTS) which perhaps be temporary in occasional ketamine users but 
continuous use might eventually lead to permanent scarring and damage, 
and development of KIC. 
 
6.2 Is there a possible link between KIC and other chronic 
non-bacterial cystitis conditions i.e. interstitial cystitis (IC) 
and eosinophilic cystitis (EC)? 
Interstitial cystitis (IC) has been puzzling scientists and clinicians for many 
decades. It is particularly difficult to diagnose IC in the initial stages of the 
disease not only clinically, but also on the basis of investigations as 
patients may not have developed the classical signs of disease (i.e. 
bladder glommerulations, hunner’s ulcer). Although the National Institute 
of Diabetes and Digestive and Kidney Diseases (NIDDK) has devised a 
criterion for the diagnosis of IC but it is used mainly for research purposes. 
As there are no objective biomarkers to diagnose IC in clinical practice, it 
is essentially a diagnosis of exclusion. Most patients with LUTS are initially 
diagnosed with other conditions such as overactive bladder, recurrent 
urinary tract infection, prostatitis or chronic pelvic pain syndrome. One 
unfortunate consequence of this is that the clinician/researcher has been 
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limited from developing new hypotheses based on the actual disease 
beginnings and instead has been channelled into focusing on patients with 
late-phase disease and all the secondary effects of the disease process 
[97]. 
The difficulty in developing objective specific biomarkers for IC may be 
becasue it is not a single disease but a collection of subset of conditions 
with different pathologies the endpoint of whom all is bladder damage and 
development of LUTS. We therefore may need more than one biomarker 
to diagnose the specific subtypes of IC for the development and delivery of 
more targeted therapy.  
Eosinophilic cystitis (EC) was first described in 1960 [98] and although EC 
is classed as a separate clinical diagnosis from IC, it is not possible to 
separate IC from EC confidently on the basis of clinical presentation alone. 
This raises the possibility that the aetiopathological mechanism of disease 
development in EC may be similar to IC in some respect and that EC may 
represent a subset of IC for whom we have found a diagnostic criterion 
(LUTS and eosinophilic infiltration of involved bladder tissue) but there are 
still subsets of IC which we do not know of. 
Clinical presentation of KIC patients is with non-bacterial cystitis similar to 
IC and EC. From the literature review and our clinical experience, it is 
rather difficult to distinguish these conditions on the basis of clinical 
presentation alone. The common presenting signs/symptoms in these 
diseases include one or more of dysuria, suprapubic pain, nocturia, urinary 
frequency and urgency ([2, 3, 13, 16-18, 39, 45, 56, 72] and reviewed by 
[23, 24, 27, 28, 31, 32, 46, 55, 56]). In addition, urge incontinence and 
haematuria in patients with KIC and EC have also been reported ([2, 13, 
16-18, 72] and reviewed by [55, 56]). 
A small contracted bladder at late stage of disease is evident on 
radiological investigations as well as urodynamics in all three conditions. 
Additionally, upper tract involvement has been described in the literature in 
both KIC [2, 13, 18] and less commonly in EC [57, 73]. But from our 
 99 
clinical experience, it is possible that long standing IC can also affect the 
upper renal tracts.  
Cystoscopy in all cases shows varying degrees of bladder inflammation 
with one or more of epithelial inflammation, neovascularisation, petechial 
haemorrhages and erythematous and/or oedematous bladder mucosa but 
additionally might also show glommerulations or Hunner’s ulcer in cases of 
IC ([2, 73] and reviewed by [28]).  
Although all biopsies in non-bacterial cystitis demonstrate infiltration of 
involved tissue by non-specific inflammatory cells as a result of chronic 
inflammation ([2, 13, 16, 17, 48, 49, 52, 76] and reviewed by [47]), 
eosinophils have been reported additionally in cases of KIC and EC ([16, 
18, 72] and reviewed by [74, 75]). It may be possible to further differentiate 
KIC and EC on the basis of histology as KIC biopsies have been reported 
to additionally demonstrate urothelial atypia [16, 18].  
The only immunohistochemistry studies we found in literature on non-
bacterial cystitis were those on IC and KIC patients. Increased expression 
of Ki67 (proliferation marker) has been demonstrated in KIC specimens 
[16, 18] but absent in IC specimens in one study [53] and down regulated 
in another study [99]. 
 
6.2.1 Conclusions 
From literature review it is evident that there are considerable similarities 
between the clinical presentation and investigation findings of KIC mainly 
to EC but also to IC. It is therefore possible that the mechanisms behind 
development of all these conditions have some similarities as well and that 
KIC may be a good model to study both EC and IC, once mechanisms 
behind development of KIC are understood.  
KIC is a relatively new condition with the first literature report only 
published in 2007 [11]. The advantage in using KIC as a research model 
to understand EC and IC will be that although the mechanism of disease 
development is currently unknown, the causative agent is known and 
therefore effective research models can be developed. 
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As mentioned before, IC may represent an endpoint of different diseases 
with multiple aetiologies and EC may be a part of this spectrum of 
currently separately recognised illnesses. Therefore, it may not be 
possible to use the KIC model to understand all conditions in IC but it is 
expected that it will certainly be useful in a subset of patients as the 
symptomatic endpoint in all of them is troublesome lower urinary tract 
symptoms. 
 
6.3 Implications of the research 
Due to the increasing use of ketamine by both clinicians and recreational 
drug abusers, all medical practitioners need to be aware of ketamine-
induced cystitis (KIC) as a disease.  
The main advances in knowledge this research project has made are that; 
1. Both ketamine and its metabolite nor-ketamine are toxic to normal 
human urothelial cells. 
2. Daily use of ketamine may be more toxic to normal human urothelial 
cells than occasional use. 
3. Despite above findings, not everyone using analgesic ketamine 
seems to be at the risk of developing KIC. 
4. The mechanism of action of ketamine on normal human urothelial 
cells may be two fold; direct toxic effect and via a receptor mediated 
pathway. 
5. Ketamine possibly leads to the development of symptoms of KIC by 
causing inflammation in the normal human urothelial cells. 
6. Drug history of ketamine use/abuse should be sought from every 
patient presenting with lower urinary tract symptoms and before 
diagnosing them with non-bacterial cystitis. 
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6.4 Future direction of research 
The experiments so far have provided some valuable initial information 
and on the basis of these results, future direction of research will be as 
below: 
1. Based on the initial immunohistochemistry experiments results and 
advice/discussion with Dr J Stahlschmidt, immunolabelling with the 
following antibodies will be further performed in the current three 
representative individual KIC tissues; 
a) AB-PAS with diastase digestion on the one tissue block (KIC3b) 
from patient KIC3 showing columnar metaplasia to assess if 
there is mucus glandular metaplasia. 
b) Calponin as a myocyte marker and, NFP and S-100 as 
neuronal cell markers to assess and differentiate between the 
anti-human NGFR positive stromal population.   
c) Bcl-2 to assess apoptosis in the KIC tissue. 
d) Cd1a to assess the presence of Langerhans cells (antigen 
presenting cells to other cells such as T-cells). 
Once all the above antibodies are completed, the results will be 
assessed and a final antibody panel will be decided to perform on the 
remaining KIC tissues in future work to explore the possible 
mechanisms of development of KIC. 
2. NHU cells form a tight barrier and the transurothelial electrical 
resistance (TER) is one of the highest recorded for any tissue [79]. 
Ketamine may be causing its effects by damage to this urinary barrier 
and measurement of TER of ketamine affected NHU cells may be a 
useful avenue to explore the above. It will be interesting to see at 
what concentrations of ketamine the NHU cells lose their TER and 
therefore their barrier function. This in turn may be useful to validate 
the toxic doses of ketamine established by the cell biology 
experiments.  
3. Experiments to establish the urothelial receptor possibly responsible 
for the action of ketamine. 
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7 Appendix  
7.1 Suppliers 
Abcam 330 Cambridge Science Park 
Cambridge, UK 
CB4 0FL 
 
AbD Serotec                  Endeavour House  
                                            Langford Lane  
                                        Kidlington, UK  
                                               OX5 1GE  
 
Adobe Ltd                    3 Roundwood Avenue 
                                               Stockley Park 
                                               Uxbridge, UK 
                                    UB11 1AY 
 
AnalaR    Unit 15  
The Birches, Willard Way 
Imberhorne Industrial Estate 
East Grinstead 
West Sussex, UK 
RH19 1XZ 
 
BD                                  The Danby Building 
(Becton, Dickinson                Edmund Halley Road 
and company)                        Oxford Science Park,  
                                               Oxford, England  
                                             OX4 4DQ 
 
BDH                              BDH Laboratory supplies 
                                    Poole, UK 
                                       BH15 1TD 
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Bio-Rad Bio-Rad Laboratories Ltd  
Bio-Rad House  
Maxted Road 
Hemel Hempstead 
Hertfordshire, UK  
HP2 7DX 
 
Co-Star Ltd.              40 Portman Square 
                                           5th Floor 
                                   London, UK 
                                   W1H 6LT  
 
Cymbus    Units J&K  
Eagle Close  
Chandlers Ford 
Hampshire, UK 
SO53 4NF 
 
DAKO Dako UK Ltd 
Cambridge House 
St Thomas Place, Ely 
Cambridgeshire, UK  
CB7 4EX 
 
Fisher Scientific   Bishop Meadow Road  
Loughborough  
Leicestershire, UK 
LE11 5RG 
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Hewlett-Packard         Amen Corner 
Cain Road  
Bracknell  
Berkshire, UK 
RG12 1HN 
 
Invitrogen  3 Fountain Drive 
Inchinnan Business Park 
Paisley, UK 
PA4 9RF 
 
Leica Balliol Business Park West 
Benton Lane 
Newcastle upon Tyne, UK 
NE12 8EW 
 
Merck Boulevard Industrial Park 
Padge Road 
Beeston 
Nottingham, UK 
NG9 2JR 
 
NIKON Nikon Precision Europe GmbH 
Stadium House, Alderstone Road 
Livingston, West Lothian, Scotland 
EH54 7DN 
 
Novocastra    Davy Avenue Knowlhill 
                                               Milton Keynes, UK 
MK5 8LB  
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Olympus Olympus UK Ltd 
KeyMed House, Stock Road 
Southend-on-Sea, Essex, UK 
SS2 5QH 
 
PALL Corporation       Europa House 
                                           Havant Street 
                                            Portsmouth, Hampshire, UK 
                                                     PO1 3PD 
 
Pfizer     Walto Oaks  
Tadworth 
Surrey, UK 
KT20 7NS 
 
Progen A division of G H Zeal Ltd 
8 Deer Park Road, Merton 
London, UK 
SW19 3UU 
 
Raymond A Lamb Ltd.     Unit 4/5, Park View 
                                         Eastbourne  
East Sussex, UK 
BN23 6QE 
 
Rockland     Lorne Laboratories Limited 
Immunohistochemicals  Unit 1 Danehill 
                                               Cutbush Park Industrial Estate 
                                              Lower Earley 
                                               Reading, UK 
                                               RG6 4UT 
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SARSTEDT Ltd.            68, Boston Road 
                                         Beaumont Leys 
                                       Leicester, UK 
                                      LE4 1AW 
 
Scientific Laboratories      Wilford industrial estate 
Supplies Ltd.            Ruddington Lane                                                          
      Wilford, Nottingham, England 
                                         NG11 7EP 
 
Sempermed    Semperit Technische Produkte  
Gesellschaft m.b.H. 
         Modecenterstraße 22 | A-1031  
Vienna 
 
Sigma-Aldrich Co. Ltd  The Old Brickyard 
     New Road 
     Gillingham, Dorset, UK  
                                            SP8 4XT  
 
Sigma Imaging Ltd  13 Little Mundells 
     Welwyn Garden City 
     Hertfordshire, UK 
     AL7 1EW 
 
STARLAB Ltd.              Unit 4 Tanners Drive 
                                        Blakelands 
                                       Milton Keynes, UK 
                                       MK14 5NA                                               
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Sterilin Limited             Parkway 
                                     Pen-y-Fan Industrial Estate 
                                  Newport, UK 
                                  NP11 3EF 
 
TOCRIS    Tocris House 
IO Centre 
Moorend Farm Avenue 
Bristol, UK 
BS11 0QL 
                               
VECTOR    3 Accent Park  
Bakewell Road 
Orton Southgate  
Peterborough, UK 
PE2 6XS 
 
World Precision   Astonbury Farm Business Centre 
Instruments    Aston, Stevenage 
                                               Herts, UK  
                                               SG2 7EG 
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7.2 Recipes 
 
7.2.1 Cell Biology 
1) KSFMC: 0.5 ml of CT + 25mg BPE + 500μl (2.5µg) EGF + 500ml 
bottle of KSFM. Stored at 4oC. 
2) CT: 1mg Cholera Toxin Powder-Sigma C8052 + 33.3ml KSFM. 
Stored in dark at 4oC. 
3) Stripper Medium: 500ml HBSS (without Ca2+ and Mg2+) Gibco 
14170-088 containing 10mM HEPES Buffer + 1ml Trasylol 
(500,000KIU) + 50ml 1% EDTA. Stored at 4oC. 
4) Transport Medium: 500ml HBSS containing 140mg/l CaCl2 and 
100mg/l MgCl2 + 10mM HEPES Buffer + 1ml Trasylol (500,000KIU). 
Stored at 4oC. 
5) TI: 100mg Trypsin Inhibitor Sigma T6522 + 5ml PBS. Solution filter 
sterilised with 0.2μm filter. Stored at -20oC. 
6) TV: 20ml Trypsin-Sigma T4549 + 4ml 1% EDTA + 176ml HBSS 
(without Ca2+ and Mg2+). Stored at -20oC. 
7) 0.1% EDTA: 1g EDTA Disodium salt (BDH 100935V) + 1000ml of 
PBS (made from 10x DPBS (Gibco 14200-067) in Elga distilled water 
(ddH2O)). Stored at ambient temperature. 
8) Freezing Mix: 10%DMSO + 10% Serum + KSFMC 
9) AB: 1 part AB dye + 9 parts KSFMC (1:10) 
10) Ketamine: LOT No. 016K1629, Catalogue No. K2753-5G, Formula 
weight 274019g/mol, purchased from Sigma-Aldrich. 
11) 10mM Ketamine solution: 27.4mg Ketamine + 10ml KSFMC 
(filtered using 0.2μm filter before use). 
12) 1mM Ketamine solution: 2.7mg + 1ml KSFMC (filtered using 0.2μm 
filter before use). 
13) Nor-Ketamine: Formula weight 260.16, CAS No. 35211-10-0, kind 
gift from Pfizer. 
14) 10mM Nor-Ketamine solution: 26.5mg Nor-Ketamine + 10ml 
KSFMC (filtered using 0.2μm filter before use). 
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15) 1mM Nor Ketamine solution: 2.6mg Nor-Ketamine + 1ml KSFMC 
(filtered using 0.2μm filter before use). 
16) MK-801 maleate: Formula weight 337.37, CAS No. 77086-22-7, 
purchased from TOCRIS. 
17) 100mM MK-801 maleate solution in DMSO: 33.7mg MK-801 + 1ml 
DMSO. 
18) 100μM MK-801 maleate solution in KSFMC: 1μl of 100mM MK-801 
maleate in DMSO solution + 1ml of KSFMC. 
 
7.2.2 Histology 
1) 10mM Citric Acid: 1.47g Citric Acid powder + 700ml of distilled 
water + pellets of NaOH to adjust pH to 6.0. 
2) 100ml 3% H2O2 in distilled water: 10ml 30% H2O2 + 90ml distilled 
water. 
3) 100ml 3% H2O2 in PBS: 10ml 30% H2O2 + 90ml PBS. 
4) TBS Buffer: 25ml 2M Tris pH 7.6 (242.28g/L) solution + 50ml 3M 
NaCl (175.32g/L) solution, made up to 1L with distilled water. 
5) Strep AB/HRP complex: 1 drop solution A + 1 drop solution B 
+2.5ml TBS. 
6) DAB solution: 2 Sigma Fast DAB tablets (one from silver and other 
from gold wrapper) + 5ml distilled water. 
7) Scott’s Tap Water: 100ml 20% MgSO4 + 50 ml 7% NaHCO3 + 
850ml distilled water. 
8) 0.1% Calcium Chloride: 1g CaCl2 + 900ml distilled water + NaOH 
pellets to adjust pH to 7.8. 
9) 0.1% Trypsin solution: Pre-warm 100ml 0.1% CaCl2 pH 7.8 to 37oC 
+ 0.1g Trypsin. 
10) Haematoxylin: Solution 1 (3g Haematoxylin + 20ml absolute 
ethanol) + Solution 2 (0.3g Sodium Iodate + 1g Citric Acid + 50g 
Chloral Hydrate + 50g Aluminium Potassium Sulphate + 850ml 
distilled water) + 120ml Glycerol. Stored in dark, filtered before use. 
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7.3 Abbreviations 
 
AB                               Alamar Blue 
AB-PAS   Alcian Blue-Periodic Acid Schiff staining 
AB-PAS-D   AB-PAS with diastase digestion 
BPE                            Bovine Pituitary extract 
CaCl2    Calcium chloride 
CIS    Carcinoma in situ 
CK              Cytokeratin 
CT                              Cholera toxin 
DAB    3,3-Diaminobenzidine 
DMSO   Dimethylsulfoxide 
EC                              Eosinophilic cystitis 
EDTA                        Ethylenediaminetetra-acetic acid 
EGF                            Epidermal Growth Factor 
HBSS    Hank’s balanced salt solution 
HEPES N-2 Hydroxyethyl piperazine-N-2 ethane 
sulphonic acid 
HLA-DR                    Human Leukocyte Antigen-DR 
H&E                           Haematoxylin and Eosin 
H2O2    Hydrogen Peroxide 
IC                               Interstitial cystitis 
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IHC    Immunohistochemistry 
KIC                            Ketamine-induced cystitis 
KSFM                        Keratinocyte serum free medium 
KSFMC                       KSFM + BPE + EGF + CT 
LUTS     Lower urinary tract symptoms 
NHU                           Normal human urothelial 
PBS    Phosphate buffered saline  
TBS    Tris buffered saline 
TI                                Trypsin inhibitor 
TV                               Trypsin Versene 
UPK                         Uroplakin 
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